BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72. [PMID: 18177818 DOI: 10.1016/s1470-2045(07)70410-2] [Cited by in Crossref: 1032] [Cited by in F6Publishing: 431] [Article Influence: 79.4] [Reference Citation Analysis]
Number Citing Articles
1 Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U, Morgenstern A. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 2014;41:2106-19. [PMID: 25070685 DOI: 10.1007/s00259-014-2857-9] [Cited by in Crossref: 176] [Cited by in F6Publishing: 158] [Article Influence: 25.1] [Reference Citation Analysis]
2 Fouché M, Bouffard Y, Le Goff MC, Prothet J, Malavieille F, Sagnard P, Christin F, Hayi-Slayman D, Pasquer A, Poncet G, Walter T, Rimmelé T. Intraoperative carcinoid syndrome during small-bowel neuroendocrine tumour surgery. Endocr Connect 2018;7:1245-50. [PMID: 30352418 DOI: 10.1530/EC-18-0324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
3 Tadashi T. Carcinoid Tumors of Digestive Organs: a Clinicopathologic Study of 13 Case. Gastroent Res. 2009;2:35-37. [PMID: 27956948 DOI: 10.4021/gr2009.01.1268] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
4 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574] [Reference Citation Analysis]
5 Schwarz C, Kaczirek K, Bodingbauer M. Liver resection for non-colorectal metastases. Eur Surg 2018;50:113-6. [PMID: 29875799 DOI: 10.1007/s10353-018-0528-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Lv Y, Huang C, Xu H, Han X, Zhang L, Mao W, Ji Y, Jin D, Lou W, Xu X. Clinicopathological Characteristics of the primary and metastatic Hepatic Neuroendocrine Tumors and the relevant Prognosis-Related Factors: A Retrospective Study of 81 Cases in a Single Chinese Center. J Cancer. 2018;9:479-487. [PMID: 29483952 DOI: 10.7150/jca.22157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
7 Magalhães D, Sampaio IL, Ferreira G, Bogalho P, Martins-Branco D, Santos R, Duarte H. Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. J Endocrinol Invest 2019;42:249-60. [PMID: 29949120 DOI: 10.1007/s40618-018-0911-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
8 Sherman SK, Maxwell JE, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR. GIPR expression in gastric and duodenal neuroendocrine tumors. J Surg Res 2014;190:587-93. [PMID: 24565507 DOI: 10.1016/j.jss.2014.01.044] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
9 Lawrence B, Gustafsson BI, Kidd M, Modlin I. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin North Am 2010;39:615-28. [PMID: 20951920 DOI: 10.1016/j.gtc.2010.08.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
10 Salyers WJ, Vega KJ, Munoz JC, Trotman BW, Tanev SS. Neuroendocrine tumors of the gastrointestinal tract: Case reports and literature review. World J Gastrointest Oncol 2014; 6(8): 301-310 [PMID: 25132927 DOI: 10.4251/wjgo.v6.i8.301] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
11 Furukori M, Imai K, Karasaki H, Watanabe K, Oikawa K, Miyokawa N, Taniguchi M, Furukawa H. Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors. World J Gastroenterol 2014; 20(47): 17949-17954 [PMID: 25548493 DOI: 10.3748/wjg.v20.i47.17949] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
12 Døssing KB, Binderup T, Kaczkowski B, Jacobsen A, Rossing M, Winther O, Federspiel B, Knigge U, Kjær A, Friis-Hansen L. Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1. Genes (Basel) 2014;6:1-21. [PMID: 25546138 DOI: 10.3390/genes6010001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
13 Ruebel K, Leontovich AA, Stilling GA, Zhang S, Righi A, Jin L, Lloyd RV. MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol. 2010;23:367-375. [PMID: 20037573 DOI: 10.1038/modpathol.2009.161] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
14 Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008; 14(35): 5377-5384 [PMID: 18803349 DOI: 10.3748/wjg.14.5377] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 78] [Article Influence: 7.2] [Reference Citation Analysis]
15 Bösch F, Altendorf-Hofmann A, Jacob S, Auernhammer CJ, Spitzweg C, Boeck S, Schubert-Fritschle G, Werner J, Kirchner T, Angele MK, Knösel T. Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor. J Clin Med 2020;9:E3368. [PMID: 33096620 DOI: 10.3390/jcm9103368] [Reference Citation Analysis]
16 Dias AR, Azevedo BC, Alban LBV, Yagi OK, Ramos MFKP, Jacob CE, Barchi LC, Cecconello I, Ribeiro U, Zilberstein B. GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE. Arq Bras Cir Dig. 2017;30:150-154. [PMID: 29257854 DOI: 10.1590/0102-6720201700020016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
17 Corinaldesi R, Stanghellini V, Barbara G, Tomassetti P, De Giorgio R. Clinical approach to diarrhea. Intern Emerg Med 2012;7 Suppl 3:S255-62. [PMID: 23073866 DOI: 10.1007/s11739-012-0827-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
18 Yang X, Cao Y, Chen C, Liu L, Wang C, Liu S. Primary neuroendocrine breast carcinomas: a retrospective analysis and review of literature. Onco Targets Ther 2017;10:397-407. [PMID: 28176908 DOI: 10.2147/OTT.S113736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
19 Er LM, Wu ML, Gao Y, Wang SJ, Li Y. Identification of sequence polymorphisms in the displacement loop region of mitochondrial DNA as a risk factor for gastroenteropancreatic neuroendocrine neoplasm. J Clin Lab Anal 2017;31. [PMID: 27704598 DOI: 10.1002/jcla.22078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
20 Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G. Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. World J Gastrointest Endosc 2010; 2(10): 325-334 [PMID: 21160582 DOI: 10.4253/wjge.v2.i10.325] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
21 Kuiper P, Hawinkels LJ, Jonge-Muller ES, Biemond I, Lamers CB, Verspaget HW. Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2011; 17(2): 219-225 [PMID: 21245995 DOI: 10.3748/wjg.v17.i2.219] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
22 Medley L, Morel AN, Farrugia D, Reed N, Hayward N, Davies JM, Kirichek O, Thakker RV, Talbot DC. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 2011;104:1067-70. [PMID: 21386841 DOI: 10.1038/bjc.2011.76] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
23 Cui T, Hurtig M, Elgue G, Li SC, Veronesi G, Essaghir A, Demoulin JB, Pelosi G, Alimohammadi M, Öberg K, Giandomenico V. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS One 2010;5:e16010. [PMID: 21209860 DOI: 10.1371/journal.pone.0016010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
24 Chen Y, Ohki R. p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis. Int J Mol Sci 2020;21:E4098. [PMID: 32521808 DOI: 10.3390/ijms21114098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 Wang YH, Lin Y, Xue L, Wang JH, Chen MH, Chen J. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China. BMC Endocr Disord. 2012;12:30. [PMID: 23194346 DOI: 10.1186/1472 -6823-12-30] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 van Adrichem RC, van der Lely AJ, Huisman M, Kramer P, Feelders RA, Delhanty PJ, de Herder WW. Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors? Endocr Connect 2016;5:143-51. [PMID: 27215920 DOI: 10.1530/EC-16-0021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
27 Franchi G, Manzoni MF. Cytological Ki-67 in pancreatic endocrine tumors: a new "must"? Gland Surg 2014;3:219-21. [PMID: 25493251 DOI: 10.3978/j.issn.2227-684X.2014.08.02] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
28 Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, Li J, Hua R, Liu Q, Sun YW. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroenterol 2017; 23(3): 516-524 [PMID: 28210088 DOI: 10.3748/wjg.v23.i3.516] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
29 Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Haustermans K, Van Cutsem E, Verbruggen A, Bogaerts K, Verslype C, Deroose CM. Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2014;41:1141-57. [PMID: 24668274 DOI: 10.1007/s00259-013-2670-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
30 Benson III AB, Broder MS, Cai B, Chang E, Neary MP, Papoyan E. Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis. World J Gastroenterol 2017; 23(33): 6128-6136 [PMID: 28970728 DOI: 10.3748/wjg.v23.i33.6128] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Hirai M, Matsumoto K, Ueyama H, Fukushima H, Murakami T, Sasaki H, Nagahara A, Yao T, Watanabe S. A case of neuroendocrine tumor G1 with unique histopathological growth progress. World J Gastrointest Endosc 2013; 5(12): 605-609 [PMID: 24368937 DOI: 10.4253/wjge.v5.i12.605] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
32 Doi M, Ikawa O, Taniguchi H, Kawamura T, Katsura K. Multiple rectal carcinoid tumors in monozygotic twins. Clin J Gastroenterol 2016;9:215-21. [PMID: 27334481 DOI: 10.1007/s12328-016-0662-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
33 Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol. 2017;9:189-199. [PMID: 28344664 DOI: 10.1177/1758834016678149] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
34 Kobara H, Mori H, Rafiq K, Fujihara S, Nishiyama N, Ayaki M, Yachida T, Tani J, Miyoshi H, Kamada H. Indications of endoscopic submucosal dissection for symptomatic benign gastrointestinal subepithelial or carcinoid tumors originating in the submucosa. Mol Clin Oncol. 2013;1:1002-1008. [PMID: 24649284 DOI: 10.3892/mco.2013.177] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
35 Schizas D, Mastoraki A, Kirkilesis GI, Sioulas AD, Papanikolaou IS, Misiakos EP, Arkadopoulos N, Liakakos T. Neuroendocrine Tumors of the Esophagus: State of the Art in Diagnostic and Therapeutic Management. J Gastrointest Cancer. 2017;48:299-304. [PMID: 28656561 DOI: 10.1007/s12029-017-9978-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
36 Rossi RE, Conte D, Elli L, Branchi F, Massironi S. Endoscopic techniques to detect small-bowel neuroendocrine tumors: A literature review. United European Gastroenterol J 2017;5:5-12. [PMID: 28405316 DOI: 10.1177/2050640616658220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
37 Vinjamuri S, Gilbert TM, Banks M, McKane G, Maltby P, Poston G, Weissman H, Palmer DH, Vora J, Pritchard DM, Cuthbertson DJ. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer 2013;108:1440-8. [PMID: 23492685 DOI: 10.1038/bjc.2013.103] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 5.5] [Reference Citation Analysis]
38 Feng X, Wei G, Wang W, Zhang Y, Zeng Y, Chen M, Chen Y, Chen J, Zhou Z, Li Y. Nomogram for individually predicting overall survival in rectal neuroendocrine tumours. BMC Cancer 2020;20:865. [PMID: 32907602 DOI: 10.1186/s12885-020-07328-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 An JK, Woo JJ, Kang JH, Kim EK. Small-cell neuroendocrine carcinoma of the breast. J Korean Surg Soc 2012;82:116-9. [PMID: 22347714 DOI: 10.4174/jkss.2012.82.2.116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
40 Kim SH, Park CH, Ki HS, Jun CH, Park SY, Kim HS, Choi SK, Rew JS. Endoscopic treatment of duodenal neuroendocrine tumors. Clin Endosc 2013;46:656-61. [PMID: 24340261 DOI: 10.5946/ce.2013.46.6.656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
41 Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D, Kountourakis P. Chromogranin A as a valid marker in oncology: Clinical application or false hopes? World J Methodol 2017; 7(1): 9-15 [PMID: 28396845 DOI: 10.5662/wjm.v7.i1.9] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
42 Lee HS, Moon HS, Kwon IS, Park JH, Kim JS, Kang SH, Lee ES, Kim SH, Sung JK, Lee BS, Jeong HY. Comparison of conventional and modified endoscopic mucosal resection methods for the treatment of rectal neuroendocrine tumors. Surg Endosc 2021;35:6055-65. [PMID: 33094828 DOI: 10.1007/s00464-020-08097-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Cullinane C, Waldeck K, Kirby L, Rogers BE, Eu P, Tothill RW, Hicks RJ. Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. Sci Rep 2020;10:10196. [PMID: 32576907 DOI: 10.1038/s41598-020-67199-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
44 Gajate P, Martínez-Sáez O, Alonso-Gordoa T, Grande E. Emerging use of everolimus in the treatment of neuroendocrine tumors. Cancer Manag Res 2017;9:215-24. [PMID: 28684922 DOI: 10.2147/CMAR.S113382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
45 Zhang Y, Li C, Chen M. Prognostic value of immunohistochemical factors in esophageal small cell carcinoma (ESCC): analysis of clinicopathologic features of 73 patients. J Thorac Dis 2018;10:4023-31. [PMID: 30174845 DOI: 10.21037/jtd.2018.06.26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Bogaerts K, Haustermans K, Nackaerts K, Van Cutsem E, Verslype C, Verbruggen A, Deroose CM. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol 2016;26:900-9. [PMID: 26162577 DOI: 10.1007/s00330-015-3882-1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
47 Srirajaskanthan R, Caplin ME, Waugh MG, Watkins J, Meyer T, Hsuan JJ, Beaumont NJ. Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes. Mol Cell Proteomics 2010;9:656-66. [PMID: 20019050 DOI: 10.1074/mcp.M900401-MCP200] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
48 Thapa P, Parghane R, Basu S. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites. World J Nucl Med 2017;16:223-8. [PMID: 28670182 DOI: 10.4103/1450-1147.207283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Jensen RT. Cancer: a roadmap for the land of small tumors. Nat Rev Endocrinol 2011;7:319-21. [PMID: 21556022 DOI: 10.1038/nrendo.2011.73] [Reference Citation Analysis]
50 Ni SJ, Sheng WQ, Du X. Pathologic research update of colorectal neuroendocrine tumors. World J Gastroenterol 2010; 16(14): 1713-1719 [PMID: 20380002 DOI: 10.3748/wjg.v16.i14.1713] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
51 Schimmack S, Lawrence B, Svejda B, Alaimo D, Schmitz-Winnenthal H, Fischer L, Büchler MW, Kidd M, Modlin I. The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms. Cancer 2012;118:2763-75. [PMID: 21990041 DOI: 10.1002/cncr.26592] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
52 Perren A, Schmitt A, Komminoth P, Pavel M. [Classification of gastro-entero-pancreatic neuroendocrine tumors]. Radiologe 2009;49:198-205. [PMID: 19224191 DOI: 10.1007/s00117-008-1781-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Genc CG, Klümpen HJ, van Oijen MGH, van Eijck CHJ, Nieveen van Dijkum EJM. A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands. World J Surg 2018;42:490-7. [PMID: 29018912 DOI: 10.1007/s00268-017-4278-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
54 Mizutani G, Nakanishi Y, Watanabe N, Honma T, Obana Y, Seki T, Ohni S, Nemoto N. Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry. Acta Histochem Cytochem 2012;45:167-76. [PMID: 22829710 DOI: 10.1267/ahc.12006] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
55 Imam R, Chang Q, Black M, Yu C, Cao W. CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor. BMC Cancer 2021;21:320. [PMID: 33765961 DOI: 10.1186/s12885-021-08045-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Bruera G, Giuliani A, Romano L, Chiominto A, Di Sibio A, Mastropietro S, Cosenza P, Ricevuto E, Schietroma M, Carlei F; Oncology Network ASL1 Abruzzo. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice. BMC Cancer 2019;19:960. [PMID: 31619203 DOI: 10.1186/s12885-019-6214-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
57 Fischer L, Mehrabi A, Büchler MW. [Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy]. Chirurg 2011;82:583-90. [PMID: 21656305 DOI: 10.1007/s00104-011-2069-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
58 de Mestier L, Neuzillet C, Hentic O, Kianmanesh R, Hammel P, Ruszniewski P. Prolonged survival in a patient with neuroendocrine tumor of the cecum and diffuse peritoneal carcinomatosis. Case Rep Gastroenterol. 2012;6:205-210. [PMID: 22649333 DOI: 10.1159/000338740] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
59 Caldarella A, Crocetti E, Paci E. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry. Pathol Oncol Res. 2011;17:759-763. [PMID: 21476126 DOI: 10.1007/s12253-011-9382-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
60 Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. J Nucl Med 2018;59:1699-705. [PMID: 29653971 DOI: 10.2967/jnumed.118.209841] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
61 Kim MK. Endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors. Gut Liver 2012;6:405-10. [PMID: 23170141 DOI: 10.5009/gnl.2012.6.4.405] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
62 Kipnis ST, Hung M, Kumar S, Heckert JM, Lee H, Bennett B, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Eads JR, Katona BW. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. JAMA Netw Open 2021;4:e212274. [PMID: 33755166 DOI: 10.1001/jamanetworkopen.2021.2274] [Reference Citation Analysis]
63 Khalil A, Ewald J, Marchese U, Autret A, Garnier J, Niccoli P, Piana G, Poizat F, Giovannini M, Delpero JR, Turrini O. A single-center experience with pancreatic cystic neuroendocrine tumors. World J Surg Oncol 2020;18:208. [PMID: 32799893 DOI: 10.1186/s12957-020-01994-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials 2020;21:141. [PMID: 32024533 DOI: 10.1186/s13063-019-3888-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
65 Zhang L, Yang Z, Chen Q, Li M, Zhu X, Wan D, Xie H, Zheng S. Mixed adenoendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review. Oncol Lett 2019;18:1585-96. [PMID: 31423226 DOI: 10.3892/ol.2019.10502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
66 Maqsood MH, Tameez Ud Din A, Khan AH. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review. Cureus. 2019;11:e3986. [PMID: 30972265 DOI: 10.7759/cureus.3986] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
67 Schottenfeld D, Beebe-Dimmer JL, Vigneau FD. The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol. 2009;19:58-69. [PMID: 19064190 DOI: 10.1016/j.annepidem.2008.10.004] [Cited by in Crossref: 147] [Cited by in F6Publishing: 116] [Article Influence: 12.3] [Reference Citation Analysis]
68 Wong KP, Tsang JS, Lang BH. Role of surgery in pancreatic neuroendocrine tumor. Gland Surg 2018;7:36-41. [PMID: 29629318 DOI: 10.21037/gs.2017.12.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
69 Svejda B, Kidd M, Timberlake A, Harry K, Kazberouk A, Schimmack S, Lawrence B, Pfragner R, Modlin IM. Serotonin and the 5-HT7 receptor: the link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors. Cancer Sci 2013;104:844-55. [PMID: 23578138 DOI: 10.1111/cas.12174] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
70 Chandra P, Shetye B, Chakravarty R, Mukherjee A, Pandey U, Jha AK, Purandare N, Shah S, Agrawal A, Ram R, Dash A, Rangarajan V. Initial Clinical Experience with 68Ga-DOTA-NOC Prepared Using 68Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based 68Ge/68Ga Generator and Freeze-dried DOTA-NOC Kits. World J Nucl Med 2017;16:140-4. [PMID: 28553181 DOI: 10.4103/1450-1147.203072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Huang SF, Kuo IM, Lee CW, Pan KT, Chen TC, Lin CJ, Hwang TL, Yu MC. Comparison study of gastrinomas between gastric and non-gastric origins. World J Surg Oncol. 2015;13:202. [PMID: 26077245 DOI: 10.1186/s12957-015-0614-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
72 Shao QQ, Zhao BB, Dong LB, Cao HT, Wang WB. Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies. World J Gastroenterol 2019; 25(32): 4673-4681 [PMID: 31528093 DOI: 10.3748/wjg.v25.i32.4673] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
73 Fottner C, Ferrata M, Weber MM. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose? Rev Endocr Metab Disord. 2017;18:393-410. [PMID: 29256148 DOI: 10.1007/s11154-017-9438-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
74 Carr JC, Sherman SK, Wang D, Dahdaleh FS, Bellizzi AM, O'Dorisio MS, O'Dorisio TM, Howe JR. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors. Ann Surg Oncol 2013;20 Suppl 3:S739-46. [PMID: 24114056 DOI: 10.1245/s10434-013-3318-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
75 Shen H, Yu Z, Zhao J, Li XZ, Pan WS. Early diagnosis and treatment of gastrointestinal neuroendocrine tumors. Oncol Lett. 2016;12:3385-3392. [PMID: 27900009 DOI: 10.3892/ol.2016.5062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
76 Zhang X, Ma L, Bao H, Zhang J, Wang Z, Gong P. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study. BMC Endocr Disord. 2014;14:54. [PMID: 25001493 DOI: 10.1186/1472-6823-14-54] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
77 Froelich MF, Schnitzer ML, Holzgreve A, Gassert FG, Gresser E, Overhoff D, Schwarze V, Fabritius MP, Nörenberg D, von Münchhausen N, Hokamp NG, Auernhammer CJ, Ilhan H, Todica A, Rübenthaler J. Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors. Diagnostics (Basel) 2021;11:334. [PMID: 33670457 DOI: 10.3390/diagnostics11020334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Lines KE, Vas Nunes RP, Frost M, Yates CJ, Stevenson M, Thakker RV. A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control. Endocr Connect 2017;6:232-42. [PMID: 28420716 DOI: 10.1530/EC-17-0040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
79 Lapa C, Werner RA, Bluemel C, Lueckerath K, Muegge DO, Strate A, Haenscheid H, Schirbel A, Allen-Auerbach MS, Bundschuh RA, Buck AK, Herrmann K. Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. EJNMMI Res 2014;4:74. [PMID: 25977880 DOI: 10.1186/s13550-014-0074-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
80 Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, Reid R, Rowsell C, Shah A, Singh S, Van Uum S, Wong R. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 2010;17:49-64. [PMID: 20567626 DOI: 10.3747/co.v17i3.484] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
81 Shim JR, Kim JR, Park Y, Seo HI. Small-cell neuroendocrine carcinoma arising from an extra-hepatic bile duct: a case report. Gastroenterol Rep (Oxf) 2021;9:380-2. [PMID: 34567573 DOI: 10.1093/gastro/goaa051] [Reference Citation Analysis]
82 Kanık A, Baran M, Çayan Ö, Eliaçık K, Özdemir T, Helvacı M, Çeçen E. Vasoactive intestinal peptide releasing tumor which caused to chronic watery diarrhea and hypokalemia. Turk Pediatri Ars 2014;49:160-2. [PMID: 26078654 DOI: 10.5152/tpa.2014.1054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
83 Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. J Gastrointest Surg. 2015;19:152-160; discussion 160. [PMID: 25118642 DOI: 10.1007/s11605-014-2624-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 7.6] [Reference Citation Analysis]
84 Liu Q, Polydorides AD. Diagnosis and prognostic significance of extramural venous invasion in neuroendocrine tumors of the small intestine. Mod Pathol 2020;33:2318-29. [PMID: 32514164 DOI: 10.1038/s41379-020-0585-1] [Reference Citation Analysis]
85 Li TT, Qiu F, Qian ZR, Wan J, Qi XK, Wu BY. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol 2014; 20(1): 118-125 [PMID: 24415864 DOI: 10.3748/wjg.v20.i1.118] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
86 Goksu SY, Ozer M, Beg MS, Sanford NN, Ahn C, Fangman BD, Goksu BB, Verma U, Sanjeevaiah A, Hsiehchen D, Jones AL, Kainthla R, Kazmi SM. Racial/Ethnic Disparities and Survival Characteristics in Non-Pancreatic Gastrointestinal Tract Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2990. [PMID: 33076486 DOI: 10.3390/cancers12102990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, Salmon A, Glaser B, Chisin R, Mishani E, J Gross D. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 2011;13:583-93. [PMID: 20652423 DOI: 10.1007/s11307-010-0374-1] [Cited by in Crossref: 97] [Cited by in F6Publishing: 80] [Article Influence: 9.7] [Reference Citation Analysis]
88 Schütte K, Bornschein J, Kuester D, Wieners G, Malfertheiner P. [Fulminant duodenal bleeding as first manifestation of a neuroendocrine carcinoma of the pancreatic head]. Med Klin (Munich) 2010;105:291-5. [PMID: 20455052 DOI: 10.1007/s00063-010-1043-5] [Reference Citation Analysis]
89 Thomas K, Voros BA, Meadows-Taylor M, Smeltzer MP, Griffin R, Boudreaux JP, Thiagarajan R, Woltering EA, Ramirez RA. Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs). Cancers (Basel) 2020;12:E206. [PMID: 31947598 DOI: 10.3390/cancers12010206] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
90 Zitzmann K, Ailer G, Vlotides G, Spoettl G, Maurer J, Göke B, Beuschlein F, Auernhammer CJ. Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. Int J Oncol. 2013;43:1824-1832. [PMID: 24100469 DOI: 10.3892/ijo.2013.2130] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
91 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Reference Citation Analysis]
92 Broder MS, Cai B, Chang E, Neary MP. Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database. BMC Pulm Med 2018;18:135. [PMID: 30103725 DOI: 10.1186/s12890-018-0678-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Berzaczy D, Giraudo C, Haug AR, Raderer M, Senn D, Karanikas G, Weber M, Mayerhoefer ME. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clin Nucl Med 2017;42:669-74. [PMID: 28682844 DOI: 10.1097/RLU.0000000000001753] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 10.3] [Reference Citation Analysis]
94 Iwata R, Maruyama M, Ito T, Nakano Y, Kanemura Y, Koike T, Oe S, Yoshimura K, Nonaka M, Nomura S, Sugimoto T, Yamada H, Asai A. Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor. Med Mol Morphol 2017;50:211-9. [PMID: 28516286 DOI: 10.1007/s00795-017-0160-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Shi H, Jiang C, Zhang Q, Qi C, Yao H, Lin R. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm. Diagn Pathol 2020;15:108. [PMID: 32917216 DOI: 10.1186/s13000-020-01030-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Posorski N, Kaemmerer D, Ernst G, Grabowski P, Hoersch D, Hommann M, von Eggeling F. Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases. Clin Exp Metastasis 2011;28:637-47. [PMID: 21681495 DOI: 10.1007/s10585-011-9397-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
97 Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res 2017;9:495-503. [PMID: 28860831 DOI: 10.2147/CEOR.S140866] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
98 Giovacchini G, Nicolas G, Freidank H, Mindt TL, Forrer F. Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy. Eur J Nucl Med Mol Imaging 2011;38:1675-82. [PMID: 21553088 DOI: 10.1007/s00259-011-1826-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
99 Berardi R, Morgese F, Torniai M, Savini A, Partelli S, Rinaldi S, Caramanti M, Ferrini C, Falconi M, Cascinu S. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol 2016; 8(4): 389-401 [PMID: 27096034 DOI: 10.4251/wjgo.v8.i4.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
100 Alexandraki K, Angelousi A, Boutzios G, Kyriakopoulos G, Rontogianni D, Kaltsas G. Management of neuroendocrine tumors of unknown primary. Rev Endocr Metab Disord 2017;18:423-31. [PMID: 29199361 DOI: 10.1007/s11154-017-9437-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
101 Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16(36): 4519-4525 [PMID: 20857521 DOI: 10.3748/wjg.v16.i36.4519] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
102 Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors. Oncologist. 2016;21:671-675. [PMID: 27226359 DOI: 10.1634/theoncologist.2015-0470] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
103 Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer. 2014;14:184. [PMID: 24628963 DOI: 10.1186/1471-2407-14-184] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
104 Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, Doi R, Shimatsu A, Nishida T, Komoto I, Hirata Y, Nakamura K, Igarashi H, Jensen RT, Wiedenmann B, Imamura M. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010;45:234-43. [PMID: 20058030 DOI: 10.1007/s00535-009-0194-8] [Cited by in Crossref: 246] [Cited by in F6Publishing: 177] [Article Influence: 22.4] [Reference Citation Analysis]
105 Tamagno G, Sheahan K, Skehan SJ, Geoghegan JG, Fennelly D, Collins CD, Maguire D, Traynor O, Brophy DP, Cantwell C, Swan N, McGowan L, O'Toole D, O'Shea D. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor. Endocrine. 2013;44:504-509. [PMID: 23471696 DOI: 10.1007/s12020-013-9910-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
106 Vorster M, Modiselle MR, Corbett CS, Lawal IO, Buscombe JR, Sathekge MM. First Results and Experience with PRRT in South Africa. World J Nucl Med 2018;17:86-93. [PMID: 29719482 DOI: 10.4103/wjnm.WJNM_25_17] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
107 Kanno-Okada H, Mitsuhashi T, Mabe K, Shimoda T, Matsuno Y. Composite neuroendocrine tumor and adenocarcinoma of the rectum. Diagn Pathol. 2017;12:85. [PMID: 29228981 DOI: 10.1186/s13000-017-0674-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Sun W, Wu S, Han X, Yang C. Effectiveness of Endoscopic Treatment for Gastrointestinal Neuroendocrine Tumors: A Retrospective Study. Medicine (Baltimore) 2016;95:e3308. [PMID: 27082572 DOI: 10.1097/MD.0000000000003308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
109 Rokstad AM, Gustafsson BI, Espevik T, Bakke I, Pfragner R, Svejda B, Modlin IM, Kidd M. Microencapsulation of small intestinal neuroendocrine neoplasm cells for tumor model studies. Cancer Sci 2012;103:1230-7. [PMID: 22435758 DOI: 10.1111/j.1349-7006.2012.02282.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
110 Ram P, Penalver JL, Lo KBU, Rangaswami J, Pressman GS. Carcinoid Heart Disease: Review of Current Knowledge. Tex Heart Inst J 2019;46:21-7. [PMID: 30833833 DOI: 10.14503/THIJ-17-6562] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
111 Osamura RY. Roles of pathologists in molecular targeted cancer therapy. J Cell Mol Med 2009;13:4286-90. [PMID: 19891708 DOI: 10.1111/j.1582-4934.2009.00960.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Huguet I, Lamas C, Vera R, Lomas A, Quilez RP, Grossman A, Botella F. Medullary thyroid carcinoma and duodenal calcitonin-secreting neuroendocrine tumour: more than coincidence? Endocrinol Diabetes Metab Case Rep 2013;2013:130021. [PMID: 24616764 DOI: 10.1530/EDM-13-0021] [Reference Citation Analysis]
113 Shin WY, Lee KY, Ahn SI, Park SY, Park KM. Cutaneous metastasis as an initial presentation of a non-functioning pancreatic neuroendocrine tumor. World J Gastroenterol 2015; 21(33): 9822-9826 [PMID: 26361431 DOI: 10.3748/wjg.v21.i33.9822] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
114 Rampurwala MM, Kumar A, Kannan S, Kowalczyk P, Khera S. Non-functioning pancreatic neuroendocrine tumors--a case report and review of literature. J Gastrointest Cancer 2011;42:257-62. [PMID: 20967573 DOI: 10.1007/s12029-010-9223-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
115 Han X, Cui Y, Yang C, Sun W, Wu J, Gao Y, Xue H, Li X, Shen L, Peng Y, Zhang H, Hu Y, Zhong L, Chen X, Ge Z. Endoscopic biopsy in gastrointestinal neuroendocrine neoplasms: a retrospective study. PLoS One 2014;9:e103210. [PMID: 25068592 DOI: 10.1371/journal.pone.0103210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
116 van Adrichem RC, Hofland LJ, Feelders RA, De Martino MC, van Koetsveld PM, van Eijck CH, de Krijger RR, Sprij-Mooij DM, Janssen JA, de Herder WW. Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. Endocr Connect 2013;2:172-7. [PMID: 24042314 DOI: 10.1530/EC-13-0052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
117 Salaria S, Means A, Revetta F, Idrees K, Liu E, Shi C. Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors. Am J Clin Pathol. 2015;144:642-648. [PMID: 26386086 DOI: 10.1309/AJCPMZY5P9TWNJJV] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
118 Grillo F, Valle L, Ferone D, Albertelli M, Brisigotti MP, Cittadini G, Vanoli A, Fiocca R, Mastracci L. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment? Endocrine 2017;57:494-502. [PMID: 28726181 DOI: 10.1007/s12020-017-1364-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
119 Wang H, Cheng Y, Zhang J, Zang J, Li H, Liu Q, Wang J, Jacobson O, Li F, Zhu Z, Chen X. Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study. Theranostics 2018;8:3308-16. [PMID: 29930731 DOI: 10.7150/thno.25919] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
120 Johnston ME 2nd, Carter MM, Wilson GC, Ahmad SA, Patel SH. Surgical management of primary pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:578-89. [PMID: 32655937 DOI: 10.21037/jgo.2019.12.09] [Reference Citation Analysis]
121 Wolin EM, Leyden J, Goldstein G, Kolarova T, Hollander R, Warner RRP. Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States. Pancreas 2017;46:639-47. [PMID: 28328615 DOI: 10.1097/MPA.0000000000000818] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
122 Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomed Res Int 2017;2017:9856140. [PMID: 29349087 DOI: 10.1155/2017/9856140] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
123 Norlén O, Montan H, Hellman P, Stålberg P, Sundin A. Preoperative 68Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions. World J Surg 2018;42:498-505. [PMID: 29159606 DOI: 10.1007/s00268-017-4364-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
124 Iliyas M, Dona D, Devi U, Noorunnisa N. Primary small cell neuroendocrine carcinoma of the anterior mediastinum presenting with trepopnea. BMJ Case Rep 2018;11:e225014. [PMID: 30567086 DOI: 10.1136/bcr-2018-225014] [Reference Citation Analysis]
125 Wang Y, Huang K, Chen J, Luo Y, Zhang Y, Jia Y, Xu L, Chen M, Huang B, Ni D, Li ZP, Feng ST. Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis. Contrast Media Mol Imaging 2018;2018:6037273. [PMID: 30510495 DOI: 10.1155/2018/6037273] [Reference Citation Analysis]
126 Kidd M, Modlin I, Öberg K. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat Rev Clin Oncol 2016;13:691-705. [PMID: 27273044 DOI: 10.1038/nrclinonc.2016.85] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
127 Fang C, Wang W, Feng X, Sun J, Zhang Y, Zeng Y, Wang J, Chen H, Cai M, Lin J, Chen M, Chen Y, Li Y, Li S, Chen J, Zhou Z. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer 2017;117:1544-50. [PMID: 28949958 DOI: 10.1038/bjc.2017.315] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
128 Komaç Ö, Bengi G, Sağol Ö, Akarsu M. C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group. World J Gastrointest Oncol 2019; 11(2): 139-152 [PMID: 30788040 DOI: 10.4251/wjgo.v11.i2.139] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
129 Namikawa T, Oki T, Kitagawa H, Okabayashi T, Kobayashi M, Hanazaki K. Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation. Med Mol Morphol. 2013;46:34-40. [PMID: 23306663 DOI: 10.1007/s00795-012-0006-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
130 Mahajan S, O'Donoghue J, Weber W, Bodei L. Integrating Early Rapid Post-Peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting. J Nucl Med Radiat Ther 2019;10:395. [PMID: 31057988 DOI: 10.4172/2155-9619.1000395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Kumar T, Gupta B, Das P, Madhusudhan KS. The rare case of a cystic pancreatic neuroendocrine tumor. Autops Case Rep 2020;10:e2020171. [PMID: 33344296 DOI: 10.4322/acr.2020.171] [Reference Citation Analysis]
132 Klöppel G, Scherübl H. [Neuroendocrine tumors of the stomach. Risk stratification and therapy]. Pathologe 2010;31:182-7. [PMID: 20306044 DOI: 10.1007/s00292-009-1268-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
133 Pan J, Bao Q, Enders G. The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor. Front Oncol 2020;10:546. [PMID: 32373532 DOI: 10.3389/fonc.2020.00546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Ito T, Igarashi H, Jensen RT. Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas 2012;41:505-7. [PMID: 22504376 DOI: 10.1097/MPA.0b013e318249a92a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
135 Gut P, Waligórska-Stachura J, Czarnywojtek A, Sawicka-Gutaj N, Bączyk M, Ziemnicka K, Fischbach J, Woliński K, Kaznowski J, Wrotkowska E, Ruchała M. Management of the hormonal syndrome of neuroendocrine tumors. Arch Med Sci 2017;13:515-24. [PMID: 28507564 DOI: 10.5114/aoms.2016.60311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
136 Ferrarotto R, Testa L, Riechelmann RP, Sahade M, Siqueira LT, Costa FP, Hoff PM. Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. Rare Tumors 2013;5:e35. [PMID: 24179647 DOI: 10.4081/rt.2013.e35] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
137 Kwon MJ, Kang HS, Soh JS, Lim H, Kim JH, Park CK, Park HR, Nam ES. Lymphovascular invasion in more than one-quarter of small rectal neuroendocrine tumors. World J Gastroenterol 2016; 22(42): 9400-9410 [PMID: 27895428 DOI: 10.3748/wjg.v22.i42.9400] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
138 Dumitrascu T, Dima S, Herlea V, Tomulescu V, Ionescu M, Popescu I. Neuroendocrine tumours of the ampulla of Vater: clinico-pathological features, surgical approach and assessment of prognosis. Langenbecks Arch Surg. 2012;397:933-943. [PMID: 22476195 DOI: 10.1007/s00423-012-0951-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
139 Li X, Shao L, Lu X, Yang Z, Ai S, Sun F, Wang M, Guan W, Liu S. Risk factors for lymph node metastasis in gastric neuroendocrine tumor: a retrospective study. BMC Surg 2021;21:174. [PMID: 33789664 DOI: 10.1186/s12893-021-01174-7] [Reference Citation Analysis]
140 Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H. Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases. Turk J Surg 2017;33:279-83. [PMID: 29260133 DOI: 10.5152/UCD.2017.3685] [Reference Citation Analysis]
141 Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, Rilling WS, Quebbeman EJ, Agarwal DM, Pitt HA. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg. 2008;12:1951-1960. [PMID: 18709512 DOI: 10.1007/s11605-008-0640-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
142 Wong MH, Chan DL, Lee A, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N. Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). PLoS One 2016;11:e0158140. [PMID: 27362760 DOI: 10.1371/journal.pone.0158140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
143 Abdel-Rahman O. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. Tumour Biol 2014;35:10615-25. [PMID: 25230786 DOI: 10.1007/s13277-014-2612-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
144 Mafficini A, Scarpa A. Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Rev 2019;40:506-36. [PMID: 30657883 DOI: 10.1210/er.2018-00160] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 30.0] [Reference Citation Analysis]
145 Cidon EU. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol 2017; 9(1): 4-20 [PMID: 28144395 DOI: 10.4251/wjgo.v9.i1.4] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
146 Jiao X, Li Y, Wang H, Liu S, Zhang D, Zhou Y. Clinicopathological features and survival analysis of gastroenteropancreatic neuroendocrine neoplasms: a retrospective study in a single center of China. Chin J Cancer Res 2015;27:258-66. [PMID: 26157322 DOI: 10.3978/j.issn.1000-9604.2015.06.04] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
147 Yamada M, Furukawa D, Yazawa N, Izumi H, Masuoka Y, Mashiko T, Kawaguchi Y, Ogawa M, Kawashima Y, Mine T, Hirabayashi K, Nakagohri T. Undifferentiated carcinoma of the ampulla of Vater. Surg Case Rep 2017;3:9. [PMID: 28063144 DOI: 10.1186/s40792-016-0284-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Luo Y, Chen J, Huang K, Lin Y, Chen M, Xu L, Li ZP, Feng ST. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria? BMC Cancer 2017;17:154. [PMID: 28231773 DOI: 10.1186/s12885-017-3150-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
149 Srirajaskanthan R, Ahmed A, Prachialias A, Srinivasan P, Heaton N, Jervis N, Quaglia A, Vivian G, Ramage JK. ENETS TNM staging predicts prognosis in small bowel neuroendocrine tumours. ISRN Oncol. 2013;2013:420795. [PMID: 23533809 DOI: 10.1155/2013/420795] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
150 García-Carbonero R, Salazar R, Sevilla I, Isla D. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). Clin Transl Oncol 2011;13:545-51. [PMID: 21821488 DOI: 10.1007/s12094-011-0695-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
151 Bacchetti S, Bertozzi S, Londero AP, Uzzau A, Pasqual EM. Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors: a meta-analysis of observational studies. Int J Hepatol. 2013;2013:235040. [PMID: 23509630 DOI: 10.1155/2013/235040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
152 Zheng Z, Chen C, Jiang L, Zhou X, Dai X, Song Y, Li Y. Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: A population-based study. Cancer Med. 2019;8:7288-7298. [PMID: 31609098 DOI: 10.1002/cam4.2567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
153 Shin Y, Ha SY, Hyeon J, Lee B, Lee J, Jang KT, Kim KM, Park YS, Park CK. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. Cancer Res Treat. 2015;47:738-746. [PMID: 25687852 DOI: 10.4143/crt.2014.224] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
154 Fotouhi O, Ghaderi M, Wang N, Zedenius J, Kjellman M, Xu D, Juhlin CC, Larsson C. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant TERT promoter methylation, but not hot-spot mutations. Epigenetics 2019;14:1224-33. [PMID: 31322481 DOI: 10.1080/15592294.2019.1634987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Saadeh H, Abdullah N, Erashdi M, Sughayer M, Al-Kadi O. Histopathologist-level quantification of Ki-67 immunoexpression in gastroenteropancreatic neuroendocrine tumors using semiautomated method. J Med Imaging (Bellingham) 2020;7:012704. [PMID: 31824983 DOI: 10.1117/1.JMI.7.1.012704] [Reference Citation Analysis]
156 Volante M, Righi L, Berruti A, Rindi G, Papotti M. The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. Virchows Arch 2011;458:393-402. [PMID: 21344263 DOI: 10.1007/s00428-011-1060-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
157 Koumarianou A, Pectasides D, Koliou GA, Dionysopoulos D, Kolomodi D, Poulios C, Skondra M, Sgouros J, Pentheroudakis G, Kaltsas G, Fountzilas G. Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study. Biology (Basel) 2020;9:E51. [PMID: 32182791 DOI: 10.3390/biology9030051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Rübenthaler J, Auernhammer C, Harun I, Ricke J, Cyran CC. [Neuroendocrine tumors of the stomach, duodenum and pancreas : Value of (hybrid) radiological diagnostics]. Radiologe 2019;59:961-7. [PMID: 31515568 DOI: 10.1007/s00117-019-00593-1] [Reference Citation Analysis]
159 Strosberg J, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland E, Shah M, Fakih M, Takahashi S, Piha-Paul SA, O'Neil B, Thomas S, Lolkema MP, Chen M, Ibrahim N, Norwood K, Hadoux J. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clin Cancer Res 2020;26:2124-30. [PMID: 31980466 DOI: 10.1158/1078-0432.CCR-19-3014] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 41.0] [Reference Citation Analysis]
160 Sandblom V, Ståhl I, Hansson C, Olofsson Bagge R, Forssell-Aronsson E. Local treatment of liver metastases by administration of 177Lu-octreotate via isolated hepatic perfusion - A preclinical simulation of a novel treatment strategy. Surg Oncol 2019;29:148-56. [PMID: 31196481 DOI: 10.1016/j.suronc.2019.05.002] [Reference Citation Analysis]
161 Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, O’Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800-816. [PMID: 23389427 DOI: 10.1007/s00259-012-2330-6] [Cited by in Crossref: 360] [Cited by in F6Publishing: 313] [Article Influence: 45.0] [Reference Citation Analysis]
162 Nikou GC, Pazaitou-Panayiotou K, Dimitroulopoulos D, Alexandrakis G, Papakostas P, Vaslamatzis M, Kaldrymidis P, Markussis V, Koumarianou A; “G-NET-Registry” investigators. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. BMC Endocr Disord 2016;16:8. [PMID: 26872616 DOI: 10.1186/s12902-016-0089-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
163 Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Cwikla J, Baum RP, Kwekkeboom DJ, Paganelli G, Krenning EP, Modlin IM. PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging. 2018;45:1155-1169. [PMID: 29484451 DOI: 10.1007/s00259-018-3967-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 15.3] [Reference Citation Analysis]
164 Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist. 2016;21:1191-1199. [PMID: 27401895 DOI: 10.1634/theoncologist.2015-0476] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 14.0] [Reference Citation Analysis]
165 Yang X, Yang Y, Li Z, Cheng C, Yang T, Wang C, Liu L, Liu S. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One 2015;10:e0124884. [PMID: 25894842 DOI: 10.1371/journal.pone.0124884] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
166 Liu Y, Ye S, Zhu Y, He X, Pan J, Chen S, Ye B, Wang L. Impact of tumour size on metastasis and survival in patients with pancreatic neuroendocrine tumours (PNETs): A population based study. J Cancer 2019;10:6349-57. [PMID: 31772667 DOI: 10.7150/jca.27779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Ende AR, Sedarat A, Shah P, Jhala N, Fraker DL, Drebin JA, Metz DC, Kochman ML. Risk factors for aggressive nonfunctional pancreatic neuroendocrine tumors and the role of endoscopic ultrasound guided fine-needle aspiration. Endosc Ultrasound. 2016;5:49-54. [PMID: 26879167 DOI: 10.4103/2303-9027.175897] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
168 Wang X, Shi YF, Duan JH, Wang C, Tan HY. S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report. World J Clin Cases 2021; 9(24): 7146-7153 [PMID: 34540971 DOI: 10.12998/wjcc.v9.i24.7146] [Reference Citation Analysis]
169 Lines KE, Stevenson M, Filippakopoulos P, Müller S, Lockstone HE, Wright B, Grozinsky-Glasberg S, Grossman AB, Knapp S, Buck D, Bountra C, Thakker RV. Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors. Oncogenesis 2017;6:e332. [PMID: 28504695 DOI: 10.1038/oncsis.2017.30] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
170 Fraticelli P, Mattioli M, Benfaremo D, Biondi L, Cardinali M, Gabrielli A. A young man with persistent dyspepsia: the unexpected virtue of proton-pump inhibitors. Acta Biomed 2019;89:569-72. [PMID: 30657126 DOI: 10.23750/abm.v89i4.6371] [Reference Citation Analysis]
171 Philips S, Shah SN, Vikram R, Verma S, Shanbhogue AK, Prasad SR. Pancreatic endocrine neoplasms: a current update on genetics and imaging. Br J Radiol 2012;85:682-96. [PMID: 22253347 DOI: 10.1259/bjr/85014761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
172 Pedraza-Arévalo S, Gahete MD, Alors-Pérez E, Luque RM, Castaño JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord 2018;19:179-92. [PMID: 30293213 DOI: 10.1007/s11154-018-9465-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
173 Kim K, Kim SJ. Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors. Nucl Med Mol Imaging 2018;52:208-15. [PMID: 29942399 DOI: 10.1007/s13139-017-0505-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
174 Paquette CE, Kent ML, Peterson TS, Wang R, Dashwood RH, Löhr CV. Immunohistochemical characterization of intestinal neoplasia in zebrafish Danio rerio indicates epithelial origin. Dis Aquat Organ 2015;116:191-7. [PMID: 26503773 DOI: 10.3354/dao02924] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
175 Al-Suqri B. 111 In-pentetreotide SPECT CT Value in Follow-up of Patients with Neuro-Endocrine Tumors. Oman Med J 2014;29:362-4. [PMID: 25337314 DOI: 10.5001/omj.2014.95] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
176 Pasqual EM, Bertozzi S, Londero AP, Bacchetti S, Lorenzin D, Pasqualucci A, Moccheggiani F, Federici A, Vivaverlli M, Risaliti A. Long term results of hepatic resection or orthotopic liver transplantation in patients with liver metastases from gastrointestinal neuroendocrine tumors. Oncol Lett 2016;12:3563-70. [PMID: 27900037 DOI: 10.3892/ol.2016.5045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
177 Wu L, Fu J, Wan L, Pan J, Lai S, Zhong J, Chung DC, Wang L. Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget. 2017;8:4935-4947. [PMID: 27903960 DOI: 10.18632/oncotarget.13632] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
178 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
179 Kondo NI, Ikeda Y. Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surg. 2014;3:276-283. [PMID: 25493259 DOI: 10.3978/j.issn.2227-684x.2013.12.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
180 Phan AT, Dave B. The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. Cancer Med 2016;5:2953-64. [PMID: 27539383 DOI: 10.1002/cam4.742] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
181 Liu Q, Cheng Y, Zang J, Sui H, Wang H, Jacobson O, Zhu Z, Chen X. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2020;47:947-57. [PMID: 31832728 DOI: 10.1007/s00259-019-04530-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
182 Rossi RE, Invernizzi P, Mazzaferro V, Massironi S. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis. United European Gastroenterol J 2020;8:140-7. [PMID: 32213066 DOI: 10.1177/2050640619890465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
183 Kim HK, Ha SY, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST. The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. Oncotarget 2017;8:73974-80. [PMID: 29088761 DOI: 10.18632/oncotarget.18168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
184 Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282-1289. [PMID: 18780869 DOI: 10.1093/jnci/djn275] [Cited by in Crossref: 154] [Cited by in F6Publishing: 142] [Article Influence: 11.8] [Reference Citation Analysis]
185 Wanek J, Gaisberger M, Beyreis M, Mayr C, Helm K, Primavesi F, Jäger T, Di Fazio P, Jakab M, Wagner A, Neureiter D, Kiesslich T. Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells. Int J Mol Sci 2018;19:E3128. [PMID: 30321986 DOI: 10.3390/ijms19103128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
186 Roviello G, Zanotti L, Venturini S, Bottini A, Generali D. Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. Cancer Biol Ther 2016;17:883-8. [PMID: 27414404 DOI: 10.1080/15384047.2016.1210735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
187 Modlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S, Kidd M. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg. 2011;396:1145-1156. [PMID: 21523447 DOI: 10.1007/s00423-011-0794-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
188 Costa RDD, Kemp R, Santos JSD, Costa DAPD, Ardengh JC, Ribas-Filho JM, Ribas CAPM. THE ROLE OF CONVENTIONAL ECHOENDOSCOPY (EUS) IN THERAPEUTIC DECISIONS IN PATIENTS WITH NEUROENDOCRINE GASTROINTESTINAL TUMORS. Arq Bras Cir Dig 2020;33:e1512. [PMID: 32844878 DOI: 10.1590/0102-672020190001e1512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Walter T, Hervieu V, Adham M, Gincul R, Poncet G, Pilleul F, Chayvialle JA, Partensky C, Lombard-Bohas C, Scoazec JY. Primary neuroendocrine tumors of the main pancreatic duct: a rare entity. Virchows Arch 2011;458:537-46. [PMID: 21431402 DOI: 10.1007/s00428-011-1067-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
190 Nguyen AH, O'Leary MP, De Andrade JP, Ituarte PHG, Kessler J, Li D, Singh G, Chang S. Natural History of Renal Neuroendocrine Neoplasms: A NET by Any Other Name? Front Endocrinol (Lausanne) 2020;11:624251. [PMID: 33613455 DOI: 10.3389/fendo.2020.624251] [Reference Citation Analysis]
191 Cockburn KC, Toumi Z, Mackie A, Julyan P. Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumours: a Systematic Literature Review. J Gastrointest Surg 2021. [PMID: 34506015 DOI: 10.1007/s11605-021-05115-w] [Reference Citation Analysis]
192 Park DH, Choi JH, Oh D, Lee SS, Seo DW, Lee SK, Kim MH. Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: results of a pilot study. Clin Endosc. 2015;48:158-164. [PMID: 25844345 DOI: 10.5946/ce.2015.48.2.158] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 7.5] [Reference Citation Analysis]
193 Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K, Komoto I, Tanaka M, Imamura M, Jensen RT, Takayanagi R, Shimatsu A. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50:58-64. [PMID: 24499825 DOI: 10.1007/s00535-014-0934-2] [Cited by in Crossref: 179] [Cited by in F6Publishing: 144] [Article Influence: 25.6] [Reference Citation Analysis]
194 Li SC, Martijn C, Cui T, Essaghir A, Luque RM, Demoulin JB, Castaño JP, Öberg K, Giandomenico V. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. PLoS One. 2012;7:e48411. [PMID: 23119007 DOI: 10.1371/journal.pone.0048411] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
195 Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K. 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs. Ann Nucl Med 2015;29:1-7. [PMID: 25139472 DOI: 10.1007/s12149-014-0898-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
196 Hirmas N, Jadaan R, Al-Ibraheem A. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives. Nucl Med Mol Imaging 2018;52:190-9. [PMID: 29942397 DOI: 10.1007/s13139-018-0517-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
197 Tan EH, Tan CH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol 2011; 2(1): 28-43 [PMID: 21603312 DOI: 10.5306/wjco.v2.i1.28] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
198 Kotagal M, von Allmen D. Gastroenteropancreatic Neuroendocrine Tumors. Semin Pediatr Surg 2020;29:150928. [PMID: 32571513 DOI: 10.1016/j.sempedsurg.2020.150928] [Reference Citation Analysis]
199 Bösch F, Bazhin AV, Heublein S, Brüwer K, Knösel T, Reiter FP, Auernhammer CJ, Guba MO, Spitzweg C, Werner J, Angele MK. Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors. BMC Cancer 2019;19:575. [PMID: 31196127 DOI: 10.1186/s12885-019-5794-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
200 Miki M, Ito T, Hijioka M, Lee L, Yasunaga K, Ueda K, Fujiyama T, Tachibana Y, Kawabe K, Jensen RT, Ogawa Y. Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors. Jpn J Clin Oncol 2017;47:520-8. [PMID: 28334992 DOI: 10.1093/jjco/hyx032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
201 Surlin V, Ramboiu S, Ghilusi M, Plesea IE. Incidental intraoperative discovery of a pancreatic neuroendocrine tumor associated with chronic pancreatitis. Diagn Pathol 2012;7:132. [PMID: 23021468 DOI: 10.1186/1746-1596-7-132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
202 Lancellotti F, Solinas L, Telesco D, Sagnotta A, Belardi A, Balsamo G, Mancini S. A rare case of metachronous neuroendocrine tumor after a colorectal adenocarcinoma: qualitative critical review of synchronous and metachronous gastrointestinal NET. Clin J Gastroenterol 2021;14:115-22. [PMID: 33044637 DOI: 10.1007/s12328-020-01255-9] [Reference Citation Analysis]
203 Grillo F, Albertelli M, Annunziata F, Boschetti M, Caff A, Pigozzi S, Ferone D, Mastracci L. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? Endocrine 2016;53:58-62. [PMID: 26362059 DOI: 10.1007/s12020-015-0734-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
204 McDermott FD, Heeney A, Courtney D, Mohan H, Winter D. Rectal carcinoids: a systematic review. Surg Endosc. 2014;28:2020-2026. [PMID: 24584484 DOI: 10.1007/s00464-014-3430-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
205 Yadegarfar G, Friend L, Jones L, Plum LM, Ardill J, Taal B, Larsson G, Jeziorski K, Kwekkeboom D, Ramage JK; EORTC Quality of Life Group. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013;108:301-310. [PMID: 23322194 DOI: 10.1038/bjc.2012.560] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
206 Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, Scarpi E, Matteucci F, Gilardi L, Paganelli G. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:881-888. [PMID: 23443937 DOI: 10.1007/s00259-013-2369-z] [Cited by in Crossref: 78] [Cited by in F6Publishing: 51] [Article Influence: 9.8] [Reference Citation Analysis]
207 Grande E, Díez JJ, Pachón V, Carrato A. Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). Clin Transl Oncol 2010;12:481-92. [PMID: 20615825 DOI: 10.1007/s12094-010-0541-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
208 Raj N, Reidy-Lagunes D. Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30:119-133. [PMID: 26614372 DOI: 10.1016/j.hoc.2015.09.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
209 Zhou X, Xie H, Xie L, Li J, Fu W. Factors associated with lymph node metastasis in radically resected rectal carcinoids: a systematic review and meta-analysis. J Gastrointest Surg. 2013;17:1689-1697. [PMID: 23818123 DOI: 10.1007/s11605-013-2249-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
210 Lv Y, Han X, Xu XF, Ji Y, Zhou YH, Sun HC, Zhou J, Fan J, Lou WH, Huang C. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection. BMC Cancer 2019;19:335. [PMID: 30961559 DOI: 10.1186/s12885-019-5457-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
211 Kim JS, Kim YJ, Chung JW, Kim JH, Kim KO, Kwon KA, Park DK, An JS. Usefulness of endoscopic resection using the band ligation method for rectal neuroendocrine tumors. Intest Res 2016;14:164-71. [PMID: 27175117 DOI: 10.5217/ir.2016.14.2.164] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
212 Scherübl H, Cadiot G. Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance. Visc Med 2017;33:332-8. [PMID: 29177161 DOI: 10.1159/000459404] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
213 Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract. 2012;2012:287825. [PMID: 23316222 DOI: 10.1155/2012/287825] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
214 Park SB, Kim HW, Kang DH, Choi CW, Kim SJ, Nam HS. Advantage of endoscopic mucosal resection with a cap for rectal neuroendocrine tumors. World J Gastroenterol 2015; 21(31): 9387-9393 [PMID: 26309365 DOI: 10.3748/wjg.v21.i31.9387] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
215 García-Carbonero R, Vilardell F, Jiménez-Fonseca P, González-Campora R, González E, Cuatrecasas M, Capdevila J, Aranda I, Barriuso J, Matías-Guiu X; Spanish Society of Pathology., Spanish Society of Medical Oncology. Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2014;16:243-56. [PMID: 23749327 DOI: 10.1007/s12094-013-1062-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
216 Hotz HG, Bojarski C, Buhr HJ. [Neuroendocrine colorectal tumors. Surgical and endoscopic treatment]. Chirurg 2011;82:607-11. [PMID: 21656304 DOI: 10.1007/s00104-011-2072-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
217 Deguelte S, Perrier M, Hammoutene C, Cadiot G, Kianmanesh R. Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors. J Clin Med. 2020;9. [PMID: 32708330 DOI: 10.3390/jcm9072319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
218 Bauckneht M, Albano D, Annunziata S, Santo G, Guglielmo P, Frantellizzi V, Branca A, Ferrari C, Vento A, Mirabile A, Nappi AG, Evangelista L, Alongi P, Laudicella R. Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2020;10:E598. [PMID: 32824388 DOI: 10.3390/diagnostics10080598] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
219 Zanini S, Renzi S, Giovinazzo F, Bermano G. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Front Endocrinol (Lausanne). 2020;11:562505. [PMID: 33304317 DOI: 10.3389/fendo.2020.562505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
220 Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg. 2015;19:2273-2282. [PMID: 26341823 DOI: 10.1007/s11605-015-2931-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
221 Waldon K, Abbas JR, Shakir S, Afify S. Four tumours including neuroendocrine tumour of the ileum. BMJ Case Rep 2015;2015:bcr2014207135. [PMID: 25935910 DOI: 10.1136/bcr-2014-207135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
222 Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol. 2015;110:1223-1232. [PMID: 26032155 DOI: 10.1038/ajg.2015.160] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
223 Deng HY, Ni PZ, Wang YC, Wang WP, Chen LQ. Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis. 2016;8:1250-1256. [PMID: 27293844 DOI: 10.21037/jtd.2016.04.21] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
224 Han X, Xu X, Jin D, Wang D, Ji Y, Lou W. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas. 2014;43:526-531. [PMID: 24658317 DOI: 10.1097/mpa.0000000000000065] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
225 Bergeret S, Charbit J, Ansquer C, Bera G, Chanson P, Lussey-Lepoutre C. Novel PET tracers: added value for endocrine disorders. Endocrine 2019;64:14-30. [PMID: 30875057 DOI: 10.1007/s12020-019-01895-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
226 Wang Y, Chen Y, Li X, Hu W, Zhang Y, Chen L, Chen M, Chen J. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm. BMC Cancer 2018;18:691. [PMID: 29940892 DOI: 10.1186/s12885-018-4449-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
227 Dörffel Y, Wermke W. [Contrast medium sonography of neuroendocrine tumors of the gastroenteropancreatic system]. Radiologe 2009;49:206-16. [PMID: 19198796 DOI: 10.1007/s00117-008-1782-y] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
228 Gock M, Mullins CS, Harnack C, Prall F, Ramer R, Göder A, Krämer OH, Klar E, Linnebacher M. Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line. World J Gastroenterol 2018; 24(33): 3749-3759 [PMID: 30197480 DOI: 10.3748/wjg.v24.i33.3749] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
229 Kos-Kudła B, Ćwikła J, Ruchała M, Hubalewska-Dydejczyk A, Jarzab B, Krajewska J, Kamiński G. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Contemp Oncol (Pozn) 2017;21:115-22. [PMID: 28947880 DOI: 10.5114/wo.2017.68619] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
230 Shamiyeh A, Gabriel M. Laparoscopic resection of gastrointestinal neuroendocrine tumors with special contribution of radionuclide imaging. World J Gastroenterol 2014; 20(42): 15608-15615 [PMID: 25400444 DOI: 10.3748/wjg.v20.i42.15608] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
231 Vickers M, Samson B, Colwell B, Cripps C, Jalink D, El-Sayed S, Chen E, Porter G, Goel R, Villeneuve J, Sundaresan S, Asselah J, Biagi J, Jonker D, Dawson L, Letourneau R, Rother M, Maroun J, Thirlwell M, Hussein M, Tehfe M, Perrin N, Michaud N, Hammad N, Champion P, Rajan R, Burkes R, Barrette S, Welch S, Yarom N, Asmis T. Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol 2010;17:70-7. [PMID: 20651901 DOI: 10.3747/co.v17i3.610] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
232 Melosky B. Advanced typical and atypical carcinoid tumours of the lung: management recommendations. Curr Oncol 2018;25:S86-93. [PMID: 29910651 DOI: 10.3747/co.25.3808] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
233 Wang Y, Wang W, Jin K, Fang C, Lin Y, Xue L, Feng S, Zhou Z, Shao C, Chen M, Yu X, Chen J. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2017;13:1165-1174. [PMID: 28454229 DOI: 10.3892/ol.2017.5591] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
234 Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017;19:991-1002. [PMID: 29091800 DOI: 10.1016/j.neo.2017.09.002] [Cited by in Crossref: 184] [Cited by in F6Publishing: 158] [Article Influence: 46.0] [Reference Citation Analysis]
235 Kasuya K, Nagakawa Y, Suzuki M, Tanaka H, Ohta H, Itoi T, Tsuchida A. Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect. Exp Ther Med 2011;2:1047-52. [PMID: 22977618 DOI: 10.3892/etm.2011.349] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
236 Abdel-Rahman O, Fouad M. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature. J Cancer Res Clin Oncol. 2015;141:295-305. [PMID: 24990591 DOI: 10.1007/s00432-014-1757-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
237 Hoej LB, Nykjær KM, Gronbaek H. Incidence and survival of patients with small intestinal neuroendocrine tumours in a Danish NET center. ScientificWorldJournal 2012;2012:206350. [PMID: 23304081 DOI: 10.1100/2012/206350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
238 Fang C, Wang W, Zhang Y, Feng X, Sun J, Zeng Y, Chen Y, Li Y, Chen M, Zhou Z, Chen J. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. Chin J Cancer 2017;36:51. [PMID: 28637502 DOI: 10.1186/s40880-017-0218-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
239 Manoharan P, Lamarca A, Navalkissoor S, Calero J, Chan PS, Julyan P, Sierra M, Caplin M, Valle J. Safety, tolerability and clinical implementation of 'ready-to-use' 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). ESMO Open 2020;5:e000650. [PMID: 32188715 DOI: 10.1136/esmoopen-2019-000650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 He L, Deng T, Luo H. Efficacy and safety of endoscopic resection therapies for rectal carcinoid tumors: a meta-analysis. Yonsei Med J. 2015;56:72-81. [PMID: 25510749 DOI: 10.3349/ymj.2015.56.1.72] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
241 Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Ann Surg Oncol. 2009;16:481-486. [PMID: 19030935 DOI: 10.1245/s10434-008-0194-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
242 Kawasaki K, Fujii M, Sato T. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. Dis Model Mech 2018;11:dmm029595. [PMID: 29590641 DOI: 10.1242/dmm.029595] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
243 Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: Epidemiological changes in Germany. World J Gastroenterol 2013; 19(47): 9012-9019 [PMID: 24379626 DOI: 10.3748/wjg.v19.i47.9012] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 62] [Article Influence: 8.1] [Reference Citation Analysis]
244 Kim M, Lee S, Lee J, Park SH, Park JO, Park YS, Kang WK, Kim ST. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. Cancer Res Treat 2016;48:153-61. [PMID: 25779359 DOI: 10.4143/crt.2014.183] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
245 Saller J, Seydafkan S, Shahid M, Gadara M, Cives M, Eschrich SA, Boulware D, Strosberg JR, Aejaz N, Coppola D. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors. Cancer Genomics Proteomics 2019;16:309-18. [PMID: 31467225 DOI: 10.21873/cgp.20136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
246 Tian R, Jacobson O, Niu G, Kiesewetter DO, Wang Z, Zhu G, Ma Y, Liu G, Chen X. Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy. Theranostics 2018;8:735-45. [PMID: 29344302 DOI: 10.7150/thno.23491] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
247 Giovinazzo F, Schimmack S, Svejda B, Alaimo D, Pfragner R, Modlin I, Kidd M. Chromogranin A and its fragments as regulators of small intestinal neuroendocrine neoplasm proliferation. PLoS One 2013;8:e81111. [PMID: 24260544 DOI: 10.1371/journal.pone.0081111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
248 Kang SH, Kim KH, Seo SH, An MS, Ha TK, Park HK, Bae KB, Choi CS, Oh SH, Choi YK. Neuroendocrine carcinoma of the stomach: A case report. World J Gastrointest Surg 2014; 6(4): 77-79 [PMID: 24829627 DOI: 10.4240/wjgs.v6.i4.77] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
249 Kim J, Kim JH, Lee JY, Chun J, Im JP, Kim JS. Clinical outcomes of endoscopic mucosal resection for rectal neuroendocrine tumor. BMC Gastroenterol. 2018;18:77. [PMID: 29866049 DOI: 10.1186/s12876-018-0806-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
250 Bonekamp D, Raman SP, Horton KM, Fishman EK. Role of computed tomography angiography in detection and staging of small bowel carcinoid tumors. World J Radiol 2015; 7(9): 220-235 [PMID: 26435774 DOI: 10.4329/wjr.v7.i9.220] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
251 Elf AK, Johanson V, Marin I, Bergström A, Nilsson O, Svensson J, Wängberg B, Bernhardt P, Elias E. Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers (Basel) 2021;13:2035. [PMID: 33922482 DOI: 10.3390/cancers13092035] [Reference Citation Analysis]
252 Cives M, Quaresmini D, Rizzo FM, Felici C, D'Oronzo S, Simone V, Silvestris F. Osteotropism of neuroendocrine tumors: role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro. Oncotarget 2017;8:22534-49. [PMID: 28186979 DOI: 10.18632/oncotarget.15122] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
253 Sherman SK, Maxwell JE, Carr JC, Wang D, Bellizzi AM, Sue O'Dorisio M, O'Dorisio TM, Howe JR. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors. Clin Exp Metastasis 2014;31:935-44. [PMID: 25241033 DOI: 10.1007/s10585-014-9681-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
254 Hashemi J, Fotouhi O, Sulaiman L, Kjellman M, Höög A, Zedenius J, Larsson C. Copy number alterations in small intestinal neuroendocrine tumors determined by array comparative genomic hybridization. BMC Cancer 2013;13:505. [PMID: 24165089 DOI: 10.1186/1471-2407-13-505] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
255 Lithgow K, Venkataraman H, Hughes S, Shah H, Kemp-Blake J, Vickrage S, Smith S, Humphries S, Elshafie M, Taniere P, Diaz-Cano S, Dasari BVM, Almond M, Ford S, Ayuk J, Shetty S, Shah T, Geh I. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort. Sci Rep 2021;11:17947. [PMID: 34504148 DOI: 10.1038/s41598-021-97247-x] [Reference Citation Analysis]
256 O'Connor JM, Marmissolle F, Bestani C, Pesce V, Belli S, Dominichini E, Mendez G, Price P, Giacomi N, Pairola A, Loria FS, Huertas E, Martin C, Patane K, Poleri C, Rosenberg M, Cabanne A, Kujaruk M, Caino A, Zamora V, Mariani J, Dioca M, Parma P, Podesta G, Andriani O, Gondolesi G, Roca E. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol. 2014;2:673-684. [PMID: 25054030 DOI: 10.3892/mco.2014.332] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
257 Hong L, Wang Y, Zhang T, Zhang C, Wang L, Wang L, Wang Z, Zhong J. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population. Med Sci Monit 2020;26:e926635. [PMID: 33141811 DOI: 10.12659/MSM.926635] [Reference Citation Analysis]
258 Schwarze V, Marschner C, Grosu S, Rübenthaler J, Knösel T, Clevert DA. [Modern sonographic imaging of abdominal neuroendocrine tumors]. Radiologe 2019;59:1002-9. [PMID: 31440790 DOI: 10.1007/s00117-019-00586-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
259 Ono K, Shiozawa E, Ohike N, Fujii T, Shibata H, Kitajima T, Fujimasa K, Okamoto N, Kawaguchi Y, Nagumo T, Tazawa S, Homma M, Yamochi-Onizuka T, Norose T, Yoshida H, Murakami M, Tate G, Takimoto M. Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: A retrospective study of 136 patients. Oncol Lett 2018;15:2123-30. [PMID: 29434915 DOI: 10.3892/ol.2017.7569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
260 Choi HH, Kim JS, Cheung DY, Cho YS. Which endoscopic treatment is the best for small rectal carcinoid tumors? World J Gastrointest Endosc 2013; 5(10): 487-494 [PMID: 24147192 DOI: 10.4253/wjge.v5.i10.487] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
261 Bílek R, Vlček P, Šafařík L, Michalský D, Novák K, Dušková J, Václavíková E, Widimský J Jr, Zelinka T. Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers (Basel) 2019;11:E586. [PMID: 31027285 DOI: 10.3390/cancers11040586] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
262 Modlin IM, Drozdov I, Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One. 2013;8:e63364. [PMID: 23691035 DOI: 10.1371/journal.pone.0063364] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 10.6] [Reference Citation Analysis]
263 Du S, Wang Z, Sang X, Lu X, Zheng Y, Xu H, Xu Y, Chi T, Zhao H, Wang W, Cui Q, Zhong S, Huang J, Mao Y. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia. Medicine (Baltimore) 2015;94:e388. [PMID: 25590842 DOI: 10.1097/MD.0000000000000388] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
264 Wang YH, Lin Y, Xue L, Wang JH, Chen MH, Chen J. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China. BMC Endocr Disord. 2012;12:30. [PMID: 23194346 DOI: 10.1186/1472-6823-12-30] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
265 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
266 Melosky B. Low Grade Neuroendocrine Tumors of the Lung. Front Oncol 2017;7:119. [PMID: 28660170 DOI: 10.3389/fonc.2017.00119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
267 Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017;44:490-499. [PMID: 27704193 DOI: 10.1007/s00259-016-3533-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 11.6] [Reference Citation Analysis]
268 Izumi H, Yazawa N, Furukawa D, Masuoka Y, Yamada M, Mashiko T, Kawashima Y, Ogawa M, Kawaguchi Y, Mine T, Hirabayashi K, Nakagohri T. Laparoscopic splenopancreatectomy for an endocrine tumor with cystic changes: a case report. Clin Case Rep 2017;5:328-32. [PMID: 28265400 DOI: 10.1002/ccr3.844] [Reference Citation Analysis]
269 Chambers AJ, Longman RS, Pasieka JL, Dixon E, Rorstad O, Rach-Longman K, Jones J. Impairment of cognitive function reported by patients suffering from carcinoid syndrome. World J Surg 2010;34:1356-60. [PMID: 20127244 DOI: 10.1007/s00268-010-0404-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
270 Pinato DJ, Tan TM, Toussi ST, Ramachandran R, Martin N, Meeran K, Ngo N, Dina R, Sharma R. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer 2014;110:115-22. [PMID: 24231952 DOI: 10.1038/bjc.2013.682] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
271 Xu X, Honda K, Miura N, Hori S, Le Blanc S, Bergmann F, Gaida MM, Volkmar M, Schimmack S, Hackert T, Strobel O, Felix K. Actinin-4 splice variant - a complementary diagnostic and prognostic marker of pancreatic neuroendocrine neoplasms. J Cancer 2020;11:2318-28. [PMID: 32127958 DOI: 10.7150/jca.37503] [Reference Citation Analysis]
272 Heckert JM, Kipnis ST, Kumar S, Botterbusch S, Alderson A, Bennett B, Creamer C, Eads JR, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Katona BW. Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. Oncologist 2020;25:572-8. [PMID: 32141667 DOI: 10.1634/theoncologist.2019-0743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
273 Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A, Appetecchia M. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014;5:7. [PMID: 24570674 DOI: 10.3389/fendo.2014.00007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
274 Schimmack S, Taylor A, Lawrence B, Alaimo D, Schmitz-Winnenthal H, Büchler MW, Modlin IM, Kidd M. A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases. Epigenetics Chromatin 2014;7:15. [PMID: 25071868 DOI: 10.1186/1756-8935-7-15] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
275 Filippi L, Cianni R, Schillaci O, Bagni O. Molecular and Metabolic Imaging of Hepatic Neuroendocrine Tumors Following Radioembolization with 90Y-microspheres. Curr Med Imaging 2020;16:545-52. [PMID: 32484088 DOI: 10.2174/1573405615666190114150038] [Reference Citation Analysis]
276 Walsh JS, Newell-Price JD, DeBono M, Adaway J, Keevil B, Eastell R. Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome. J Clin Endocrinol Metab 2013;98:2902-7. [PMID: 23633214 DOI: 10.1210/jc.2012-4174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
277 Jang S, Jin H, Roy M, Ma AL, Gong S, Jaskula-Sztul R, Chen H. Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1. Cancer Med 2017;6:2142-52. [PMID: 28776955 DOI: 10.1002/cam4.1151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
278 Cukier M, Vergara R, Mendez-Rios JD, Castillo O, Barrera I, Tello E, El Achtar O, Loo Y, Tapia H, Perez G, Peña M. Neuroendocrine tumors in Panama: A nationwide database analysis. Mol Clin Oncol 2021;15:157. [PMID: 34178328 DOI: 10.3892/mco.2021.2319] [Reference Citation Analysis]
279 Cui Y, Li ZW, Li XT, Gao SY, Li Y, Li J, Zhu HC, Tang L, Cao K, Sun YS. Dynamic enhanced CT: is there a difference between liver metastases of gastroenteropancreatic neuroendocrine tumor and adenocarcinoma. Oncotarget 2017;8:108146-55. [PMID: 29296230 DOI: 10.18632/oncotarget.22554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
280 Sherman SK, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. Surgery 2013;154:1206-13; discussion 1214. [PMID: 24238043 DOI: 10.1016/j.surg.2013.04.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
281 Smith TL, Yuan Z, Cardó-Vila M, Sanchez Claros C, Adem A, Cui MH, Branch CA, Gelovani JG, Libutti SK, Sidman RL, Pasqualini R, Arap W. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas. Proc Natl Acad Sci U S A 2016;113:2466-71. [PMID: 26884209 DOI: 10.1073/pnas.1525709113] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
282 Kidd M, Gustafsson BI. Management of Gastric Carcinoids (Neuroendocrine Neoplasms). Curr Gastroenterol Rep 2012;14:467-72. [DOI: 10.1007/s11894-012-0289-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
283 Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, Grande E, Capdevila J, Aller J, Arbizu J, Jimenez-Fonseca P; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015;34:823-42. [PMID: 26433592 DOI: 10.1007/s10555-015-9598-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
284 Kleiman DA, Beninato T, Sultan S, Crowley MJ, Finnerty B, Kumar R, Panarelli NC, Liu YF, Lieberman MD, Seandel M. Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors. Ann Surg Oncol. 2014;21 Suppl 4:S672-S679. [PMID: 24854489 DOI: 10.1245/s10434-014-3787-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
285 Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2011;8:54-64. [PMID: 21808296 DOI: 10.1038/nrendo.2011.120] [Cited by in Crossref: 116] [Cited by in F6Publishing: 99] [Article Influence: 11.6] [Reference Citation Analysis]
286 Qiu W, Christakis I, Silva A, Bassett RL Jr, Cao L, Meng QH, Gardner Grubbs E, Zhao H, Yao JC, Lee JE, Perrier ND. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol (Oxf) 2016;85:400-7. [PMID: 27256431 DOI: 10.1111/cen.13119] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
287 Cha JH, Jung DH, Kim JH, Youn YH, Park H, Park JJ, Um YJ, Park SJ, Cheon JH, Kim TI, Kim WH, Lee HJ. Long-term outcomes according to additional treatments after endoscopic resection for rectal small neuroendocrine tumors. Sci Rep 2019;9:4911. [PMID: 30894571 DOI: 10.1038/s41598-019-40668-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
288 Abgral R, Bourhis D, Salaun PY. Clinical perspectives for the use of total body PET/CT. Eur J Nucl Med Mol Imaging 2021;48:1712-8. [PMID: 33742236 DOI: 10.1007/s00259-021-05293-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
289 Xie R, Fu KI, Chen SM, Tuo BG, Wu HC. Neurofibromatosis type 1-associated multiple rectal neuroendocrine tumors: A case report and review of the literature. World J Gastroenterol 2018; 24(33): 3806-3812 [PMID: 30197486 DOI: 10.3748/wjg.v24.i33.3806] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
290 Peltola E, Hannula P, Huhtala H, Metso S, Kiviniemi U, Vornanen M, Sand J, Laukkarinen J, Tiikkainen M, Schalin-Jäntti C, Arola J, Sirén J, Piiroinen A, Soinio M, Nuutila P, Söderström M, Hämäläinen H, Moilanen L, Laaksonen D, Pirinen E, Sundelin F, Ebeling T, Salmela P, Mäkinen MJ, Jaatinen P. Characteristics and Outcomes of 79 Patients with an Insulinoma: A Nationwide Retrospective Study in Finland. Int J Endocrinol 2018;2018:2059481. [PMID: 30425741 DOI: 10.1155/2018/2059481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
291 Rosentraeger MJ, Garbrecht N, Anlauf M, Raffel A, Knoefel WT, Wiedenmann B, Klöppel G. Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Arch. 2016;468:277-287. [PMID: 26649731 DOI: 10.1007/s00428-015-1890-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
292 Costa F, Gumz B. Octreotide - A Review of its Use in Treating Neuroendocrine Tumours. Eur Endocrinol 2014;10:70-4. [PMID: 29872467 DOI: 10.17925/EE.2014.10.01.70] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
293 Uppin MS, Uppin SG, Sunil CS, Hui M, Paul TR, Bheerappa N. Clinicopathologic study of neuroendocrine tumors of gastroenteropancreatic tract: a single institutional experience. J Gastrointest Oncol 2017;8:139-47. [PMID: 28280618 DOI: 10.21037/jgo.2016.12.08] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
294 Şen O, Türkçapar AG. Finding carcinoid tumor before bariatric surgery. Is preoperative endoscopy necessary? Case report. Int J Surg Case Rep 2019;62:132-4. [PMID: 31499413 DOI: 10.1016/j.ijscr.2019.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
295 Rossi RE, Garcia-Hernandez J, Meyer T, Thirlwell C, Watkins J, Martin NG, Caplin ME, Toumpanakis C. Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Ann Transl Med. 2015;3:118. [PMID: 26207246 DOI: 10.3978/j.issn.2305-5839.2015.04.23] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
296 Bowen KA, Silva SR, Johnson JN, Doan HQ, Jackson LN, Gulhati P, Qiu S, Riall TS, Evers BM. An analysis of trends and growth factor receptor expression of GI carcinoid tumors. J Gastrointest Surg 2009;13:1773-80. [PMID: 19582519 DOI: 10.1007/s11605-009-0958-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
297 Bösch F, Ilhan H, Pfahler V, Thomas M, Knösel T, Eibl V, Pratschke S, Bartenstein P, Seidensticker M, Auernhammer CJ, Spitzweg C, Guba MO, Werner J, Angele MK. Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection. Hepatobiliary Surg Nutr 2020;9:312-21. [PMID: 32509817 DOI: 10.21037/hbsn.2019.07.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
298 Donahue TR, Kazanjian KK, Isacoff WH, Reber HA, Hines OJ. Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer. J Gastrointest Surg 2010;14:1012-8. [PMID: 20309646 DOI: 10.1007/s11605-010-1187-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
299 Rodriguez-Freixinos V, Capdevila J, Pavel M, Thawer A, Baudin E, O'Toole D, Herrmann K, Welin S, Grozinsky-Glasberg S, de Herder WW, Valle JW, Herman J, Kolarova T, Bouvier C, Falconi M, Ferone D, Singh S. Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. Eur J Cancer 2021;144:200-14. [PMID: 33370645 DOI: 10.1016/j.ejca.2020.11.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
300 Ye L, Lu H, Wu L, Zhang L, Shi H, Wu HM, Tu P, Li M, Wang FY. The clinicopathologic features and prognosis of esophageal neuroendocrine carcinomas: a single-center study of 53 resection cases. BMC Cancer. 2019;19:1234. [PMID: 31852479 DOI: 10.1186/s12885-019-6420-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
301 Hallet J, Davis LE, Mahar AL, Law CHL, Isenberg-Grzeda E, Bubis LD, Singh S, Myrehaug S, Zhao H, Beyfuss K, Moody L, Coburn NG. Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes. Oncologist 2019;24:1384-94. [PMID: 31270268 DOI: 10.1634/theoncologist.2019-0112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
302 Oberg K. Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs). Theranostics 2012;2:448-58. [PMID: 22768025 DOI: 10.7150/thno.3931] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
303 Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, Hörsch D, Tiensuu Janson E, Kianmanesh R, Kos-Kudla B, Pavel M, Rinke A, Falconi M, de Herder WW; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology 2017;105:245-54. [PMID: 28253514 DOI: 10.1159/000461583] [Cited by in Crossref: 52] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
304 Pakran J, Riyaz N. Necrolytic migratory ulceration. Indian Dermatol Online J 2013;4:205-7. [PMID: 23984235 DOI: 10.4103/2229-5178.115518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
305 Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19. [PMID: 20196864 DOI: 10.1186/1756-9966-29-19] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 7.5] [Reference Citation Analysis]
306 Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T. Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature. Onco Targets Ther 2014;7:1919-26. [PMID: 25364262 DOI: 10.2147/OTT.S68573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
307 Doihara H, Nozawa K, Kojima R, Kawabata-Shoda E, Yokoyama T, Ito H. QGP-1 cells release 5-HT via TRPA1 activation; a model of human enterochromaffin cells. Mol Cell Biochem. 2009;331:239-245. [PMID: 19507004 DOI: 10.1007/s11010-009-0165-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
308 Ogimi T, Sadahiro S, Kamei Y, Chan LF, Miyakita H, Saito G, Okada K, Suzuki T, Kajiwara H. Distribution of Neuroendocrine Marker-Positive Cells in Colorectal Cancer Tissue and Normal Mucosal Tissue: Consideration of Histogenesis of Neuroendocrine Cancer. Oncology 2019;97:294-300. [PMID: 31390635 DOI: 10.1159/000501521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
309 Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH, Ames MM. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas. 2013;42:411-421. [PMID: 23211371 DOI: 10.1097/mpa.0b013e31826cb243] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
310 Kiesewetter B, Duan H, Lamm W, Haug A, Riss P, Selberherr A, Scheuba C, Raderer M. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs. Oncologist. 2019;24:255-258. [PMID: 30171068 DOI: 10.1634/theoncologist.2018-0191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
311 Baeg K, Harris C, Naparst MS, Ahn E, Thapi S, Martin J, Rustgi S, Mhango G, Wisnivesky J, Kim MK. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients. BMC Cancer 2021;21:146. [PMID: 33563241 DOI: 10.1186/s12885-021-07868-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 Schott M, Kloppel G, Raffel A, Saleh A, Knoefel WT, Scherbaum WA. Neuroendocrine neoplasms of the gastrointestinal tract. Dtsch Arztebl Int. 2011;108:305-312. [PMID: 21629514 DOI: 10.3238/arztebl.2011.0305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
313 Öberg K. Medical Therapy of Gastrointestinal Neuroendocrine Tumors. Visc Med 2017;33:352-6. [PMID: 29177164 DOI: 10.1159/000475831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
314 Schulz C, Schütte K, Malfertheiner P. Rare Neoplasia of the Stomach. Gastrointest Tumors 2015;2:52-60. [PMID: 26674659 DOI: 10.1159/000435899] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
315 Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92. [PMID: 18703061 DOI: 10.1053/j.gastro.2008.05.047] [Cited by in Crossref: 479] [Cited by in F6Publishing: 388] [Article Influence: 36.8] [Reference Citation Analysis]
316 Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med. 2016;57:708-714. [PMID: 26769865 DOI: 10.2967/jnumed.115.163865] [Cited by in Crossref: 102] [Cited by in F6Publishing: 88] [Article Influence: 20.4] [Reference Citation Analysis]
317 Tsunenari T, Aosasa S, Ogata S, Hoshikawa M, Nishikawa M, Noro T, Shinto E, Tsujimoto H, Ueno H, Hamabe F, Shinmoto H, Hase K, Yamamoto J. Synchronous neuroendocrine tumors in both the pancreas and ileum: A case report. Int J Surg Case Rep 2016;22:47-50. [PMID: 27046104 DOI: 10.1016/j.ijscr.2016.03.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
318 Zaidi MY, Lopez-Aguiar AG, Dillhoff M, Beal E, Poultsides G, Makris E, Rocha F, Crown A, Idrees K, Marincola Smith P, Nathan H, Beems M, Abbott D, Barrett JR, Fields RC, Davidson J, Cardona K, Maithel SK. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. JAMA Surg. 2019;154:134-140. [PMID: 30383112 DOI: 10.1001/jamasurg.2018.3865] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
319 Pu N, Habib JR, Bejjani M, Yin H, Nagai M, Chen J, Kinny-Köster B, Chen Q, Zhang J, Yu J, Wu W, Lou W. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021;9:329. [PMID: 33708956 DOI: 10.21037/atm-20-5348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
320 Simbolo M, Vicentini C, Mafficini A, Fassan M, Pedron S, Corbo V, Mastracci L, Rusev B, Pedrazzani C, Landoni L, Grillo F, Cingarlini S, Rindi G, Luchini C, Scarpa A, Lawlor RT. Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine. Virchows Arch 2018;473:709-17. [PMID: 30219970 DOI: 10.1007/s00428-018-2450-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
321 van Treijen MJC, Korse CM, van Leeuwaarde RS, Saveur LJ, Vriens MR, Verbeek WHM, Tesselaar MET, Valk GD. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study. Front Endocrinol (Lausanne) 2018;9:740. [PMID: 30564197 DOI: 10.3389/fendo.2018.00740] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
322 Baekdal J, Krogh J, Klose M, Holmager P, Langer SW, Oturai P, Kjaer A, Federspiel B, Hilsted L, Rehfeld JF, Knigge U, Andreassen M. Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors. Diagnostics (Basel) 2020;10:E881. [PMID: 33138020 DOI: 10.3390/diagnostics10110881] [Reference Citation Analysis]
323 李晓琼, 张华, 李健丁. 肝脏原发性神经内分泌肿瘤的研究现状. 世界华人消化杂志 2013; 21(11): 984-989 [DOI: 10.11569/wcjd.v21.i11.984] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
324 Zaidi MY, Lopez-Aguiar AG, Switchenko JM, Lipscomb J, Andreasi V, Partelli S, Gamboa AC, Lee RM, Poultsides GA, Dillhoff M, Rocha FG, Idrees K, Cho CS, Weber SM, Fields RC, Staley CA 3rd, Falconi M, Maithel SK. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. Ann Surg 2019;270:422-33. [PMID: 31283562 DOI: 10.1097/SLA.0000000000003461] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 22.0] [Reference Citation Analysis]
325 Rehfeld A, Plass M, Døssing K, Knigge U, Kjær A, Krogh A, Friis-Hansen L. Alternative polyadenylation of tumor suppressor genes in small intestinal neuroendocrine tumors. Front Endocrinol (Lausanne) 2014;5:46. [PMID: 24782827 DOI: 10.3389/fendo.2014.00046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
326 Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16:e435-e446. [PMID: 26370353 DOI: 10.1016/s1470-2045(15)00186-2] [Cited by in Crossref: 129] [Cited by in F6Publishing: 66] [Article Influence: 21.5] [Reference Citation Analysis]
327 Malla S, Kumar P, Madhusudhan KS. Radiology of the neuroendocrine neoplasms of the gastrointestinal tract: a comprehensive review. Abdom Radiol (NY) 2021;46:919-35. [PMID: 32960304 DOI: 10.1007/s00261-020-02773-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
328 Cives M, Strosberg J. Radionuclide Therapy for Neuroendocrine Tumors. Curr Oncol Rep. 2017;19:9. [PMID: 28220446 DOI: 10.1007/s11912-017-0567-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 18.0] [Reference Citation Analysis]
329 Soga J. The term "carcinoid" is a misnomer: the evidence based on local invasion. J Exp Clin Cancer Res 2009;28:15. [PMID: 19208248 DOI: 10.1186/1756-9966-28-15] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
330 Hijioka M, Ito T, Igarashi H, Fujimori N, Lee L, Nakamura T, Jensen RT, Takayanagi R. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci. 2014;105:1464-1471. [PMID: 25220535 DOI: 10.1111/cas.12533] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
331 DePalo DK, Lee RM, Lopez-Aguiar AG, Gamboa AC, Rocha F, Poultsides G, Dillhoff M, Fields RC, Idrees K, Nathan H, Abbott D, Maithel SK, Russell MC; other members of the United States Neuroendocrine Tumor Study Group. Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity? J Surg Oncol 2019;120:919-25. [PMID: 31385621 DOI: 10.1002/jso.25662] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
332 Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, Tomaszuk M, Kołodziej M, Mikołajczak R, Pawlak D, Hubalewska-Dydejczyk A. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging 2011;38:1669-74. [PMID: 21559978 DOI: 10.1007/s00259-011-1835-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
333 Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer 2018;18:1122. [PMID: 30445941 DOI: 10.1186/s12885-018-5057-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
334 Izumo W, Higuchi R, Yazawa T, Uemura S, Matsunaga Y, Shiihara M, Furukawa T, Yamamoto M. A long-term recurrence-free survival of a patient with the mixed adeno-neuroendocrine bile duct carcinoma: A case report and review of the literature. Int J Surg Case Rep 2017;39:43-50. [PMID: 28806619 DOI: 10.1016/j.ijscr.2017.07.052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
335 Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146:724-732. [PMID: 21690450 DOI: 10.1001/archsurg.2011.129] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 6.4] [Reference Citation Analysis]
336 Zhong Q, Chen QY, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Li P, Zheng CH, Huang CM. Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population-based study. Cancer Med. 2018;7:3521-3533. [PMID: 29873204 DOI: 10.1002/cam4.1598] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
337 Wang JB, Xue Z, Lu J, He QL, Zheng ZF, Xu BB, Xie JW, Li P, Xu Y, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Huang CM, Zheng CH. Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series. BMC Cancer 2020;20:1002. [PMID: 33059606 DOI: 10.1186/s12885-020-07506-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
338 Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Pathol 2021;32:309-17. [PMID: 33409812 DOI: 10.1007/s12022-020-09657-8] [Reference Citation Analysis]
339 Eriksson J, Garmo H, Hellman P, Ihre-Lundgren C. The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors. Ann Surg Oncol 2017;24:1214-20. [PMID: 27904972 DOI: 10.1245/s10434-016-5703-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
340 Faure M, Niccoli P, Autret A, Cavaglione G, Mineur L, Raoul JL. Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Mol Clin Oncol 2017;6:44-8. [PMID: 28123727 DOI: 10.3892/mco.2016.1097] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
341 Modlin IM, Drozdov I, Bodei L, Kidd M. Blood transcript analysis and metastatic recurrent small bowel carcinoid management. BMC Cancer 2014;14:564. [PMID: 25095873 DOI: 10.1186/1471-2407-14-564] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
342 Lee H, Choi HJ, Park IY. Small cell carcinoma of the gallbladder: a case report. Ann Hepatobiliary Pancreat Surg 2017;21:168-71. [PMID: 28990005 DOI: 10.14701/ahbps.2017.21.3.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
343 Zhang L, Wan D, Bao L, Chen Q, Xie H, Xu S, Lin S. Neuroendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review. Medicine (Baltimore) 2018;97:e11487. [PMID: 30024526 DOI: 10.1097/MD.0000000000011487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
344 Deng HY, Li G, Luo J, Li XR, Alai G, Lin YD. The Role of Surgery in Treating Resectable Limited Disease of Esophageal Neuroendocrine Carcinoma. World J Surg. 2018;42:2428-2436. [PMID: 29340724 DOI: 10.1007/s00268-018-4475-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
345 Di Giacinto P, Rota F, Rizza L, Campana D, Isidori A, Lania A, Lenzi A, Zuppi P, Baldelli R. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. Int J Endocrinol 2018;2018:8126087. [PMID: 30057604 DOI: 10.1155/2018/8126087] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
346 Shrikhande SV, Sirohi B, Goel M, Barreto SG. Pancreatic neuroendocrine tumors. Indian J Gastroenterol 2013;32:3-17. [PMID: 23054950 DOI: 10.1007/s12664-012-0257-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
347 Shi H, Zhang Q, Han C, Zhen D, Lin R. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study. BMC Endocr Disord 2018;18:51. [PMID: 30055596 DOI: 10.1186/s12902-018-0274-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
348 Chan DT, Luk AO, So WY, Kong AP, Chow FC, Ma RC, Lo AW. Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis. BMC Endocr Disord. 2016;16:12. [PMID: 26911576 DOI: 10.1186/s12902-016-0087-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
349 Thomasian NM, Kamel IR, Bai HX. Machine intelligence in non-invasive endocrine cancer diagnostics. Nat Rev Endocrinol 2021. [PMID: 34754064 DOI: 10.1038/s41574-021-00543-9] [Reference Citation Analysis]
350 Mirzaei S, Revheim ME, Raynor W, Zehetner W, Knoll P, Zandieh S, Alavi A. 64Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors. Oncol Ther 2020;8:125-31. [PMID: 32700066 DOI: 10.1007/s40487-019-00104-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
351 Zhou Y, Li D, Lin Y, Yu M, Lu X, Jian Z, Na N, Hou B. Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. Onco Targets Ther 2018;11:2489-96. [PMID: 29760558 DOI: 10.2147/OTT.S152657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
352 Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses MA. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer. 2014;111:1772-1779. [PMID: 25137018 DOI: 10.1038/bjc.2014.462] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
353 Massironi S, Sciola V, Spampatti MP, Peracchi M, Conte D. Gastric carcinoids: Between underestimation and overtreatment. World J Gastroenterol 2009; 15(18): 2177-2183 [PMID: 19437556 DOI: 10.3748/wjg.15.2177] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
354 Machado MC. Surgical treatment of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. Clinics (Sao Paulo) 2012;67 Suppl 1:145-8. [PMID: 22584720 DOI: 10.6061/clinics/2012(sup01)24] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
355 Mpilla G, Aboukameel A, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, Azmi AS. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. Cancers (Basel). 2019;11. [PMID: 31795447 DOI: 10.3390/cancers11121902] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
356 Shah CP, Mramba LK, Bishnoi R, Unnikrishnan A, Duff JM, Chandana SR. Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database. J Gastrointest Oncol 2019;10:869-77. [PMID: 31602324 DOI: 10.21037/jgo.2019.05.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
357 Macedo D, Amaral T, Fernandes I, Sousa AR, Costa AL, Távora I, Quintela A, Cortes P, Costa L. The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012. ISRN Hepatol 2013;2013:702167. [PMID: 27335831 DOI: 10.1155/2013/702167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
358 Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol 2020; 26(19): 2305-2322 [PMID: 32476795 DOI: 10.3748/wjg.v26.i19.2305] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
359 Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 [PMID: 31011254 DOI: 10.3748/wjg.v25.i14.1684] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
360 Hallet J, Coburn NG, Singh S, Beyfuss K, Koujanian S, Liu N, Law CHL. Access to care and outcomes for neuroendocrine tumours: does socioeconomic status matter? Curr Oncol 2018;25:e356-64. [PMID: 30464685 DOI: 10.3747/co.35.3930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
361 Albertelli M, Dotto A, Nista F, Veresani A, Patti L, Gay S, Sciallero S, Boschetti M, Ferone D. "Present and future of immunotherapy in Neuroendocrine Tumors". Rev Endocr Metab Disord 2021;22:615-36. [PMID: 33851319 DOI: 10.1007/s11154-021-09647-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
362 Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019;10:2042018818804698. [PMID: 30800264 DOI: 10.1177/2042018818804698] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
363 Spetz J, Langen B, Rudqvist N, Parris TZ, Helou K, Nilsson O, Forssell-Aronsson E. Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice. BMC Cancer 2017;17:528. [PMID: 28789624 DOI: 10.1186/s12885-017-3524-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
364 Chiorean L, Bartos A, Pelau D, Iancu D, Ciuleanu T, Buiga R, Oancea I, Mangrau A, Iancu C, Badea R. Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment. J Med Ultrason (2001) 2015;42:271-6. [PMID: 26576584 DOI: 10.1007/s10396-014-0585-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
365 Milione M, Pusceddu S, Gasparini P, Melotti F, Maisonneuve P, Mazzaferro V, de Braud FG, Pelosi G. Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum. Cancers (Basel) 2012;4:808-20. [PMID: 24213468 DOI: 10.3390/cancers4030808] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
366 Hicks RJ. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging 2010;10 Spec no A:S83-91. [PMID: 20880795 DOI: 10.1102/1470-7330.2010.9007] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
367 Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G. Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc 2011; 3(7): 133-139 [PMID: 21860682 DOI: 10.4253/wjge.v3.i7.133] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
368 Juškys R, Poškus E, Beiša A, Gumbys L, Jocius D, Meškauskas R, Strupas K. High-grade well-differentiated neuroendocrine tumour of the cecum diagnosed following incisional hernia repair: a case report. Acta Med Litu 2020;27:17-24. [PMID: 32577092 DOI: 10.6001/actamedica.v27i1.4262] [Reference Citation Analysis]
369 Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB;  UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6-32. [PMID: 22052063 DOI: 10.1136/gutjnl-2011-300831] [Cited by in Crossref: 353] [Cited by in F6Publishing: 280] [Article Influence: 35.3] [Reference Citation Analysis]
370 Białkowska J, Kolasińska-Ćwikła A, Mroczkowska D, Sowa M, Grabarczyk Ł, Maksymowicz W, Cichocki A, Ćwikła JB. Disseminated Pancreatic Neuroendocrine Neoplasm (NEN) with an Uncommon Localisation in the Central Nervous System. A Case Report. Pol J Radiol 2017;82:120-5. [PMID: 28344687 DOI: 10.12659/PJR.899007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
371 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
372 Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, Paganelli G. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest. 2009;32:360-369. [PMID: 19636207 DOI: 10.1007/bf03345728] [Cited by in Crossref: 73] [Cited by in F6Publishing: 29] [Article Influence: 6.1] [Reference Citation Analysis]
373 Harada H, Suehiro S, Shimizu T, Katsuyama Y, Hayasaka K, Ito H. Ligation-assisted endoscopic submucosal resection with circumferential mucosal incision for duodenal carcinoid tumor. World J Gastroenterol 2015; 21(34): 10041-10044 [PMID: 26379409 DOI: 10.3748/wjg.v21.i34.10041] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
374 Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2012;39:501-11. [PMID: 22183108 DOI: 10.1007/s00259-011-2003-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
375 Kawano S, Miyashima Y, Miyabe Y, Kawai Y, Murata T, Uda M, Inokuchi T, Okada H. A case of small intestinal neuroendocrine carcinoma diagnosed using double-balloon endoscopy with long-term survival. Clin J Gastroenterol. 2018;11:240-244. [PMID: 29450787 DOI: 10.1007/s12328-018-0834-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
376 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
377 Parghane RV, Mitra A, Bannore TU, Rakshit S, Banerjee S, Basu S. Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, 90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects. World J Nucl Med 2021;20:73-81. [PMID: 33850492 DOI: 10.4103/wjnm.WJNM_52_20] [Reference Citation Analysis]
378 Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 2016;5:174-87. [PMID: 27582247 DOI: 10.1530/EC-16-0043] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 9.8] [Reference Citation Analysis]
379 Velikyan I. Prospective of ⁶⁸Ga-radiopharmaceutical development. Theranostics 2013;4:47-80. [PMID: 24396515 DOI: 10.7150/thno.7447] [Cited by in Crossref: 205] [Cited by in F6Publishing: 163] [Article Influence: 25.6] [Reference Citation Analysis]
380 Pruthi A, Pankaj P, Verma R, Jain A, Belho ES, Mahajan H. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. J Gastrointest Oncol 2016;7:449-61. [PMID: 27284479 DOI: 10.21037/jgo.2016.01.06] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
381 Shilkrut M, Sapir E, Hanasoge S, Schipper MJ, Normolle DP, Ben-Josef E, Ensminger W, Lawrence TS, Feng M. Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. Am J Clin Oncol 2018;41:326-31. [PMID: 26886946 DOI: 10.1097/COC.0000000000000276] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
382 Navalkele P, O’Dorisio MS, O’Dorisio TM, Zamba GK, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer. 2011;56:50-57. [PMID: 21108439 DOI: 10.1002/pbc.22559] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
383 Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A, Tsavaris N, Pectasides D, Dimitriadis G, Kaltsas G. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer. 2012;19:L1-L4. [PMID: 22232542 DOI: 10.1530/erc-11-0287] [Cited by in Crossref: 41] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
384 Omori S, Harada N, Toshima T, Takeishi K, Itoh S, Ikegami T, Yoshizumi T, Mori M. Multiple liver metastases originating from synchronous double cancer of neuroendocrine tumor and rectal cancer: a case report. Surg Case Rep 2020;6:36. [PMID: 32056066 DOI: 10.1186/s40792-020-0800-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Chevalier B, Dupuis H, Jannin A, Lemaitre M, Do Cao C, Cardot-Bauters C, Espiard S, Vantyghem MC. Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations. Front Endocrinol (Lausanne) 2021;12:678869. [PMID: 34025587 DOI: 10.3389/fendo.2021.678869] [Reference Citation Analysis]
386 Li DH, Wang C, Chen HJ, Huang H, Ding ZY. Clinical characteristics of the mixed form of neuroendocrine tumor in the lung: A retrospective study in 2501 lung cancer cases. Thorac Cancer 2015;6:25-30. [PMID: 26273331 DOI: 10.1111/1759-7714.12128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
387 Daskalakis K, Chatzelis E, Tsoli M, Papadopoulou-Marketou N, Dimitriadis GK, Tsolakis AV, Kaltsas G. Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms. Endocrine 2019;64:384-92. [PMID: 30280284 DOI: 10.1007/s12020-018-1773-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
388 Bösch F, Werner J, Angele MK, Guba MO. [Oligometastases of neuroendocrine tumors-extent of surgery]. Chirurg 2018;89:516-22. [PMID: 29876615 DOI: 10.1007/s00104-018-0644-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
389 Rodríguez de Lope C, Reig ME, Darnell A, Forner A. Approach of the patient with a liver mass. Frontline Gastroenterol 2012;3:252-62. [PMID: 28839677 DOI: 10.1136/flgastro-2012-100146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
390 Song W, Chen W, Zhang S, Peng J, He Y. Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy. Diagn Pathol 2012;7:163. [PMID: 23186166 DOI: 10.1186/1746-1596-7-163] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
391 Savva C, Kaye P, Soomro I, Parsons SL, James E, Madhusudan S. Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center. J Gastrointest Cancer 2018;49:85-92. [PMID: 29230683 DOI: 10.1007/s12029-017-0039-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
392 Song YL, Yu R, Qiao XW, Bai CM, Lu CM, Xiao Y, Zhong DR, Chen J, Zhao YP, Zhang TP, Song TT, Gao HL, Wan YH, Shen L, Chen J, Lv B, Hao JJ, Zhang Y, Tang L, Chen YJ. Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors. Sci Rep 2017;7:2205. [PMID: 28526880 DOI: 10.1038/s41598-017-02051-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
393 Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget 2016;7:6593-608. [PMID: 26673010 DOI: 10.18632/oncotarget.6565] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
394 Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17:17-22. [PMID: 24636662 DOI: 10.1111/hpb.12225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
395 Heo J, Jeon SW, Jung MK, Kim SK, Shin GY, Park SM, Ahn SY, Yoon WK, Kim M, Kwon YH. A tailored approach for endoscopic treatment of small rectal neuroendocrine tumor. Surg Endosc 2014;28:2931-8. [PMID: 24853847 DOI: 10.1007/s00464-014-3555-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
396 Koumarianou A, Alexandraki KI, Wallin G, Kaltsas G, Daskalakis K. Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review. J Clin Med. 2020;9. [PMID: 32521677 DOI: 10.3390/jcm9061777] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
397 Cai W, Tan Y, Ge W, Ding K, Hu H. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cancer Med 2018;7:2699-709. [PMID: 29733523 DOI: 10.1002/cam4.1507] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
398 Li Y, Wu ZQ, Xu Q, Goyal H, Xu HG. Development and Validation of Novel Nomograms Using Serum Tumor Markers for the Prediction of Preoperative Histologic Grades in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol 2021;11:681149. [PMID: 34109127 DOI: 10.3389/fonc.2021.681149] [Reference Citation Analysis]
399 Lee SH, Park SJ, Kim HH, Ok KS, Kim JH, Jee SR, Seol SY, Kim BM. Endoscopic resection for rectal carcinoid tumors: comparison of polypectomy and endoscopic submucosal resection with band ligation. Clin Endosc. 2012;45:89-94. [PMID: 22741138 DOI: 10.5946/ce.2012.45.1.89] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
400 Kulahci O, Koseci T. The Correlation of the Neutrophil-Lymphocyte Ratio and the Platelet-Lymphocyte Ratio With Pathological Findings in Neuroendocrine Tumors. Cureus 2021;13:e17164. [PMID: 34532190 DOI: 10.7759/cureus.17164] [Reference Citation Analysis]
401 Farooqui ZA, Chauhan A. Neuroendocrine Tumors in Pediatrics. Glob Pediatr Health 2019;6:2333794X19862712. [PMID: 31384627 DOI: 10.1177/2333794X19862712] [Reference Citation Analysis]
402 Bongiovanni A, Recine F, Celli M, Marcantognini G, Foca F, Liverani C, Fausti V, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature. Medicine (Baltimore) 2017;96:e8567. [PMID: 29145267 DOI: 10.1097/MD.0000000000008567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
403 Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival? Radiology. 2017;283:883-894. [PMID: 27831830 DOI: 10.1148/radiol.2016160838] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
404 Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]
405 Tan EH, Goh SW. Exploring new frontiers in molecular imaging: Emergence of 68Ga PET/CT. World J Radiol 2010; 2(2): 55-67 [PMID: 21160919 DOI: 10.4329/wjr.v2.i2.55] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
406 Capurso G, Fendrich V, Rinzivillo M, Panzuto F, Bartsch DK, Delle Fave G. Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problems. Int J Mol Sci 2012;14:30-45. [PMID: 23344019 DOI: 10.3390/ijms14010030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
407 Van Ness M, Gregg J, Wang J, Chen M. Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine. J Gastrointest Oncol 2012;3:243-51. [PMID: 22943015 DOI: 10.3978/j.issn.2078-6891.2012.017] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
408 Hommann M, Kaemmerer D, Hörsch D, Kulkarni HR, Robiller F, Baum RP. [The relevance of PET/CT for the surgical management of neuroendocrine neoplasms]. Chirurg 2014;85:500-4. [PMID: 24844432 DOI: 10.1007/s00104-013-2671-0] [Reference Citation Analysis]
409 Park JK, Paik WH, Lee K, Ryu JK, Lee SH, Kim YT. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors. Oncotarget 2017;8:49796-806. [PMID: 28591701 DOI: 10.18632/oncotarget.17964] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
410 Nagata K, Tajiri K, Shimada S, Ando T, Hosokawa A, Matsui K, Imura J, Sugiyama T. Rectal Neuroendocrine Tumor G1 with a Solitary Hepatic Metastatic Lesion. Intern Med 2017;56:289-93. [PMID: 28154272 DOI: 10.2169/internalmedicine.56.7523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
411 Schimmack S, Yang Y, Felix K, Herbst M, Li Y, Schenk M, Bergmann F, Hackert T, Strobel O. C-reactive protein (CRP) promotes malignant properties in pancreatic neuroendocrine neoplasms. Endocr Connect 2019;8:1007-19. [PMID: 31234146 DOI: 10.1530/EC-19-0132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
412 Jaskula-Sztul R, Xu W, Chen G, Harrison A, Dammalapati A, Nair R, Cheng Y, Gong S, Chen H. Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy. Biomaterials 2016;91:1-10. [PMID: 26994874 DOI: 10.1016/j.biomaterials.2016.03.010] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
413 Singh S, Law C. Multidisciplinary reference centers: the care of neuroendocrine tumors. J Oncol Pract. 2010;6:e11-e16. [PMID: 21358944 DOI: 10.1200/jop.2010.000098] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
414 Kidd M, Modlin IM, Bodei L, Drozdov I. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. Cell Mol Gastroenterol Hepatol 2015;1:131-53. [PMID: 28210673 DOI: 10.1016/j.jcmgh.2014.12.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
415 Fan JH, Zhang YQ, Shi SS, Chen YJ, Yuan XH, Jiang LM, Wang SM, Ma L, He YT, Feng CY, Sun XB, Liu Q, Deloso K, Chi Y, Qiao YL. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget. 2017;8:71699-71708. [PMID: 29069739 DOI: 10.18632/oncotarget.17599] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
416 Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford). 2010;12:361-379. [PMID: 20662787 DOI: 10.1111/j.1477-2574.2010.00175.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 78] [Article Influence: 9.4] [Reference Citation Analysis]
417 Døssing KBV, Kjær C, Vikeså J, Binderup T, Knigge U, Culler MD, Kjær A, Federspiel B, Friis-Hansen L. Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells. Genes (Basel) 2018;9:E337. [PMID: 29973528 DOI: 10.3390/genes9070337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
418 Kidd M, Modlin IM, Drozdov I. Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors. BMC Genomics 2014;15:595. [PMID: 25023465 DOI: 10.1186/1471-2164-15-595] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
419 Valous NA, Lahrmann B, Halama N, Bergmann F, Jäger D, Grabe N. Spatial intratumoral heterogeneity of proliferation in immunohistochemical images of solid tumors. Med Phys 2016;43:2936-47. [PMID: 27277043 DOI: 10.1118/1.4949003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
420 Kidd M, Drozdov I, Joseph R, Pfragner R, Culler M, Modlin I. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008;113:690-700. [PMID: 18618499 DOI: 10.1002/cncr.23700] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
421 Modrek AS, Hsu HC, Leichman CG, Du KL. Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data. Radiat Oncol. 2015;10:101. [PMID: 25902707 DOI: 10.1186/s13014-015-0411-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
422 Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, El-Rayes BF. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2019;24:911-920. [PMID: 30482824 DOI: 10.1634/theoncologist.2018-0382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
423 Hamze Z, Vercherat C, Bernigaud-Lacheretz A, Bazzi W, Bonnavion R, Lu J, Calender A, Pouponnot C, Bertolino P, Roche C. Altered MENIN expression disrupts the MAFA differentiation pathway in insulinoma. Endocr Relat Cancer. 2013;20:833-848. [PMID: 24157940 DOI: 10.1530/ERC-13-0164] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
424 Lu X, Lu C, Yang Y, Shi X, Wang H, Yang N, Yang K, Zhang X. Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000-2019): A Bibliometric Study. Front Pharmacol 2021;12:624534. [PMID: 33986664 DOI: 10.3389/fphar.2021.624534] [Reference Citation Analysis]
425 Walter T, van Brakel B, Vercherat C, Hervieu V, Forestier J, Chayvialle JA, Molin Y, Lombard-Bohas C, Joly MO, Scoazec JY. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br J Cancer. 2015;112:523-531. [PMID: 25584486 DOI: 10.1038/bjc.2014.660] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 11.3] [Reference Citation Analysis]
426 Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, Wang YH, Chen J, Lu CM. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 2014;14:64. [PMID: 25099181 DOI: 10.1186/1472-6823-14-64] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
427 Hyun JH, Lee SD, Youk EG, Lee JB, Lee EJ, Chang HJ, Sohn DK. Clinical impact of atypical endoscopic features in rectal neuroendocrine tumors. World J Gastroenterol 2015; 21(47): 13302-13308 [PMID: 26715813 DOI: 10.3748/wjg.v21.i47.13302] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
428 Silva SR, Bowen KA, Rychahou PG, Jackson LN, Weiss HL, Lee EY, Townsend CM, Evers BM. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer. 2011;128:1045-1056. [PMID: 20473929 DOI: 10.1002/ijc.25441] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
429 Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol. 2012;47:941-960. [PMID: 22886480 DOI: 10.1007/s00535-012-0642-8] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 7.7] [Reference Citation Analysis]
430 Poncet G, Faucheron JL, Walter T. Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol 2010; 16(14): 1696-1706 [PMID: 20380000 DOI: 10.3748/wjg.v16.i14.1696] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
431 Giovinazzo F, Butturini G, Monsellato D, Malleo G, Marchegiani G, Bassi C. Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. Updates Surg. 2013;65:19-24. [PMID: 23417896 DOI: 10.1007/s13304-013-0201-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
432 Bodei L, Ćwikla JB, Kidd M, Modlin IM. The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors. J Thorac Dis 2017;9:S1511-23. [PMID: 29201454 DOI: 10.21037/jtd.2017.09.82] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
433 Kubota K, Okasaki M, Minamimoto R, Miyata Y, Morooka M, Nakajima K, Sato T. Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors. Ann Nucl Med. 2014;28:1004-1010. [PMID: 25179521 DOI: 10.1007/s12149-014-0900-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
434 Park C, Ha SY, Kim ST, Kim HC, Heo JS, Park YS, Lauwers G, Lee J, Kim KM. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Oncotarget 2016;7:4024-35. [PMID: 26684240 DOI: 10.18632/oncotarget.6602] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
435 Garcia-Carbonero R, JImenez-Fonseca P, Teulé A, Barriuso J, Sevilla I; Spanish Society for Medical Oncology. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. Clin Transl Oncol 2014;16:1025-34. [PMID: 25183048 DOI: 10.1007/s12094-014-1214-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
436 Estrozi B, Bacchi CE. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases. Clinics (Sao Paulo). 2011;66:1671-1675. [PMID: 22012036 DOI: 10.1590/s1807-59322011001000002] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
437 Sharma R, Lythgoe MP, Slaich B, Patel N. Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias. Cancers (Basel) 2021;13:4181. [PMID: 34439335 DOI: 10.3390/cancers13164181] [Reference Citation Analysis]